

Appendix B: Clinical Literature Search Procedure

The literature search identified infliximab and comparator trials simultaneously, as per the NICE technology appraisal of etanercept and efalizumab. The data from this search informed the infliximab efficacy review and the indirect comparison analysis.

Medline and Embase formed the foundation of the search. These databases were combined and de-duplicated and paper selection was carried out on this combined database. The Cochrane library was also searched, but the retrieved records from this database were not systematically excluded; rather they were manually cross-checked against the results of the Medline and Embase search to ensure that no RCTs had been missed.

The figure on page 17 of the submission was intended to show how papers relating to infliximab trials only were excluded, as required out in the STA procedure manual. However since the main literature search was carried out using combined literature databases for three drugs simultaneously this figure had to be derived by hand calculation. The following should be noted about this figure:

- a) The numbers of papers written against each database include comparator medications
- b) All numbers except those of papers finally selected include duplicates

A detailed breakdown of the paper selection procedure is set out below together with a list of excluded and included papers at each step.

Breakdown of Medline/Embase Search Strategy

Total Medline Records: 334

Total Embase Records: 936

Total Medline/Embase Duplicates identified electronically: 339

Medline/Embase Combined: 1112

Further Duplicates identified Manually (n=24)

Anonymous (2006). "Efalizumab. Plaque psoriasis: Too many unknowns." Prescrire International **15**(81): 8-11.

Bhosle, M. J., S. R. Feldman, et al. (2006). "Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis." Journal of Dermatological Treatment **17**(5): 294-301.

Carlin, C. S., S. R. Feldman, et al. (2004). "A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.[see comment]." Journal of the American Academy of Dermatology **50**(6): 859-66.

Doggrell, S. A. (2004). "Efalizumab for psoriasis?" Expert Opinion on Investigational Drugs **13**(5): 551-4.

Dubertret, L., W. Sterry, et al. (2006). "Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial." British Journal of Dermatology **155**(1): 170-81.

Goedkoop, A. Y., M. C. Kraan, et al. (2004). "Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis." Annals of the Rheumatic Diseases **63**(7): 769-73.

Gordon, K. B., A. B. Gottlieb, et al. (2006). "Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.[erratum appears in J Dermatolog Treat. 2006;17(3):192]." Journal of Dermatological Treatment **17**(1): 9-17.

- Gordon, K. B., K. A. Papp, et al. (2003). "Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.[see comment][erratum appears in JAMA. 2004 Mar 3;291(9):1070]." JAMA **290**(23): 3073-80.
- Gottlieb, A. B., C. L. Leonardi, et al. (2006). "Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database." Journal of the American Academy of Dermatology **54**(3 SUPPL. 2): S92-S100.
- Gottlieb, A. B., R. T. Matheson, et al. (2003). "A randomized trial of etanercept as monotherapy for psoriasis." Archives of Dermatology **139**(12): 1627-32; discussion 1632.
- Gottlieb, A. B., T. Hamilton, et al. (2006). "Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial." Journal of the American Academy of Dermatology **54**(4 Suppl 1): S154-63.
- Guenther, L., R. G. Langley, et al. (2004). "Integrating biologic agents into management of moderate-to-severe psoriasis: A consensus of the Canadian Psoriasis Expert Panel." Journal of Cutaneous Medicine & Surgery **8**(5): 321-337.
- Iyer, S., P. Yamauchi, et al. (2002). "Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy.[see comment]." British Journal of Dermatology **146**(1): 118-21.
- Lebwohl, M. G. (2005). "Use of etanercept in the dermatology setting. A review.[erratum appears in Am J Clin Dermatol. 2005;6(3):202]." American Journal of Clinical Dermatology **6**(1): 49-59.
- Leonardi, C. L., J. L. Powers, et al. (2003). "Etanercept as monotherapy in patients with psoriasis.[see comment]." New England Journal of Medicine **349**(21): 2014-22.
- Mease, P. J., B. S. Goffe, et al. (2000). "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.[see comment]." Lancet **356**(9227): 385-90.
- Ortonne, J. P., N. Shear, et al. "Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: Results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]." Journal.
- Papp, K. A., R. Bressinck, et al. (2006). "Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial." International Journal of Dermatology **45**(5): 605-614.
- Papp, K. A., S. Tyring, et al. (2005). "A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction." British Journal of Dermatology **152**(6): 1304-12.
- Reich, K., F. O. Nestle, et al. (2005). "Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.[see comment]." Lancet **366**(9494): 1367-74.
- Schopf, R. E., H. Aust, et al. (2002). "Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab." Journal of the American Academy of Dermatology **46**(6): 886-91.
- Smith, C. H., A. V. Anstey, et al. (2005). "British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005.[erratum appears in Br J Dermatol. 2005 Nov;153(5):1092 Note: Griffiths, C E M [corrected to Griffiths, C E M]." British Journal of Dermatology **153**(3): 486-97.
- Smith, C. H., K. Jackson, et al. (2006). "Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study." British Journal of Dermatology **155**(1): 160-9.
- Tyring, S., A. Gottlieb, et al. (2006). "Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.[see comment]." Lancet **367**(9504): 29-35.

Excluded Non-English Papers (n=141)

- (2005). "[Simple and safe treatment offers new perspectives]." Krankenpflege Journal **43**(1-3): 56-7.
- Abitbol, V., F. Berenbaum, et al. (2004). "Prevention and management of tuberculosis occurring under Remicade: National recommendation. [French]." Medecine Therapeutique Pediatrie **7**(3): 220-221.
- Anandarajah, A. P. and C. T. Ritchlin (2005). "Treatment update on spondyloarthritis. [Turkish]." Sendrom **17**(11): 31-37.

- Anonymous (2003). "Efalizumab for the treatment of moderate-to-severe plaque-type psoriasis. [German]." Deutsche Apotheker Zeitung **143**(37): 54-55.
- Anonymous (2003). "News from drug research and development. [German]." Deutsche Apotheker Zeitung **143**(SUPPL.): 4-14.
- Anonymous (2004). "Further approval: Treatment of psoriasis vulgaris with etanercept. [German]." Deutsche Apotheker Zeitung **144**(44): 37-39.
- Anonymous (2004). "New drugs in 2004. [German]." Deutsche Apotheker Zeitung **144**(52): 4-20.
- Anonymous (2004). "News from drug research and development. [German]." Deutsche Apotheker Zeitung **144**(52): 21-33.
- Anonymous (2004). "Rheumatoid arthritis: Prevention of joint disorders with infliximab. [German]." Deutsche Apotheker Zeitung **144**(31): 35.
- Anonymous (2005). "New drugs in 2004. [German]." Tagliche Praxis **46**(2): 401-411.
- Anonymous (2006). "Current side-effects of drugs: Isotretinoin - A drug for acne with risk; hepatosplenic T-cell lymphoma under infliximab therapy. [German]." Tagliche Praxis **47**(4): 843-844.
- Anonymous (2006). "Efalizumab. [Spanish]." Pharmaceutical Care Espana **8**(1): 35-37.
- Anonymous (2006). "Significant progress for dermatology. The 8th meeting of the DWFA informed experts in a symposium on modern therapy management of plaque psoriasis with biologics. [German]." Haut **17**(1): 28-29.
- Antoni, C. and B. Manger (2003). "[Treatment of psoriatic arthritis with TNF alpha-antagonists]." Zeitschrift fur Rheumatologie **62**(3): 235-9.
- Antoni, C. and B. Manger (2003). "Treatment of psoriatic arthritis with TNF α -antagonists. [German]." Zeitschrift fur Rheumatologie **62**(3): 235-239.
- Antoni, C. E. and B. Manger (2004). "Biologics: A new therapeutic approach for inflammatory diseases. [German]." Internist **45**(SUPPL. 1): S31-S37.
- Arruda, L., S. Ypiranga, et al. (2004). "Systemic treatment of psoriasis - Part II: Biologic immunomodulator agents. [Portuguese, English]." Anais Brasileiros de Dermatologia **79**(4): 393-411.
- Auffret, N. (2004). "European congress on psoriasis: Sero Symposium - Paris, October 23, 2004
Efaluzimab (Raptiva) : Long-term control of psoriasis when usual systemic therapeutics cannot be used. [French]." Nouvelles Dermatologiques **23**(9): 570-571.
- Baran, W., P. Nockowski, et al. (2004). "Modern aspects of the pathogenesis and treatment of psoriatic arthritis. [Polish]." Przegląd Dermatologiczny **91**(5): 431-436.
- Benito-Ruiz, P. (2006). "Etanercept today. [Spanish]." Reumatologia Clinica **2**(SPEC. ISS. 2): 21-23.
- Bernhard, J. (2002). "Seronegative spondyloarthropathies. [German]." Therapeutische Umschau **59**(10): 529-534.
- Bianchi, L., A. Giunta, et al. (2006). "Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis." Giornale Italiano di Dermatologia e Venereologia **141**(1): 73-78.
- Boehncke, W. H. (2005). "Monoclonal antibodies in psoriasis. [German]." Arzneimittel-Forschung **55**(11): 701-702.
- Boehncke, W. H., M. Friedrich, et al. (2003). "The role of biologics into the management of psoriasis: A consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung. [German]." Journal der Deutschen Dermatologischen Gesellschaft **1**(8): 620-628.
- Boehncke, W. H., M. Friedrich, et al. (2006). "Psoriatic arthritis - An interdisciplinary challenge. [German]." Deutsches Arzteblatt **103**(21): 1455-1461.
- Brandt, J., J. Sieper, et al. (2000). "Experimental therapeutic approaches in spondyloarthropathies. [German]." Aktuelle Rheumatologie **25**(1-2): 38-42.
- Braun, J., F. Dybowski, et al. (2006). "Financial basis for the prescription of TNF-blockers in Germany. [German]." Aktuelle Rheumatologie **31**(6): 322-328.
- Burgos-Vargas, R. (2006). "Guidelines and recommendations of the Mexican College of Rheumatology on the use of biological agents in patients with rheumatic disease. [Spanish]." Reumatologia Clinica **2**(2): 78-89.

- Chen, S. L., J. Yan, et al. (2006). "Efalizumab for psoriasis: A systematic review. [Chinese]." Chinese Journal of Evidence-Based Medicine 6(4): 267-272.
- Claudepierre, P., D. Wendling, et al. (2006). "[Anti-TNF alpha in the treatment of psoriatic arthritis]." Presse Medicale 35(4 Pt 2): 647-55.
- De Groot, A. C. (2005). "Etanercept: A new treatment option for psoriasis. [Dutch]." Nederlands Tijdschrift voor Dermatologie & Venereologie 15(2): 77-86.
- De Rie, M. A. and J. D. Bos (2004). "New biologic therapies for the treatment of psoriasis." Giornale Italiano di Dermatologia e Venereologia 139(1): 3-13.
- Descalzo, M. A., D. Montero, et al. (2007). "Spanish registry for adverse events of biological therapy in rheumatic diseases (BIOBADASER): State report, January 26th, 2006. [Spanish]." Reumatologia Clinica 3(1): 4-20.
- Descamps, V. (2006). "[Efalizumab]." Annales de Dermatologie et de Venereologie 133(8-9 Pt 1): 666-78.
- Descamps, V. (2006). "Efalizumab. [French]." Annales de Dermatologie et de Venereologie 133(8): 666-678.
- Dirschka, T., U. Reinhold, et al. (2006). "[Efalizumab--therapy of moderately severe to severe plaque-psoriasis in the dermatologist's practice]." Journal der Deutschen Dermatologischen Gesellschaft 4 Suppl 1: S3-S12.
- Dirschka, T., U. Reinhold, et al. (2006). "Efalizumab therapy of moderate to severe plaque psoriasis in dermatological practice. [German]." Journal der Deutschen Dermatologischen Gesellschaft 4(SUPPL. 1): S3-S12.
- Dubertret, L. (2006). "Assessment of patient autonomy for Raptiva administration, evaluation of the PASI score and patient's auto-evaluation. [French, English]." Nouvelles Dermatologiques 25(3): 251-252.
- Dubertret, L. (2006). "Management of cutaneous reactions occurring during or after a treatment with efalizumab (Raptiva). [French]." Nouvelles Dermatologiques 25(7): 479-480.
- Fain, O. (2003). "[TNF-alpha inhibitors]." Revue du Praticien 53(18): 1989-90.
- Fantini, F. (2003). "[New drugs and treatment strategies for rheumatoid arthritis]." Recenti Progressi in Medicina 94(9): 361-79.
- Follmann, M., W. Sterry, et al. (2005). "Development of the evidence-based guidelines for psoriasis - A project of the German dermatological society (DDG). [German]." Journal der Deutschen Dermatologischen Gesellschaft 3(9): 678-689.
- Fonseca, J. E., H. Lucas, et al. (2006). "Guidelines for the diagnosis and treatment of latent tuberculosis infection and active tuberculosis in patients with inflammatory joint diseases proposed for treatment with tumour necrosis factor alpha antagonists drugs. [Portuguese]." Revista Portuguesa de Pneumologia 12(5): 603-613.
- Friedrich, M., S. Philipp, et al. (2003). "Use of biologicals in psoriasis. [German]." Zeitschrift fur Rheumatologie 62(5): 439-449.
- Friedrich, M., W. Sterry, et al. (2003). "Novel developments in the systemic treatment of psoriasis. [German]." Journal der Deutschen Dermatologischen Gesellschaft 1(1): 12-21.
- Gamo, R. and J. L. Lopez-Estebarez (2006). "Biologic therapy and psoriasis. [Spanish]." Actas Dermo-Sifiliograficas 97(1): 1-17.
- Gause, A. and A. Schnabel (2003). "[Rheumatology 2003-part I: research news concerning pathogenesis, epidemiology, diagnosis, and therapy of chronic inflammatory joint diseases]." Medizinische Klinik 98(9): 523-33.
- Geilen, C. C. (2003). "Systemic immunosuppressive drugs in the treatment of psoriasis. [German]." Aktuelle Dermatologie 29(8-9): 341-346.
- Ghislain, P. D. and L. Marot (2005). "Treating psoriasis in... 2010. [French]." Louvain Medical 124(6): S145-S148.
- Goguet, M., C. Fernandez, et al. (2005). "Assessment of efficacy and safety of infliximab in practice on 19 patients with spondylarthropathy. [French]." Journal de Pharmacie Clinique 24(2): 77-82.
- Hahn, M. and T. Schulz (2005). "[Health economic aspects of psoriasis therapy. Is inpatient topical treatment of plaque-type psoriasis in this age of biologics still appropriate from both medical and economic viewpoints?]." Hautarzt 56(6): 576-80.

- Hahn, M. and T. Schulz (2005). "Economic aspects of psoriasis therapy. Is inpatient topical treatment of plaque-type psoriasis in this age of biologics still appropriate from both medical and economic viewpoints. [German]." Hautarzt **56**(6): 576-580.
- Hellwig, B. (2003). "Inhibition of adhesion molecules: Efalizumab for the treatment of psoriasis. [German]." Deutsche Apotheker Zeitung **143**(22): 44-46.
- Herlin, T. (2002). "[Juvenile idiopathic arthritis]." Ugeskrift for Laeger **164**(34): 3941-6.
- Herlin, T. (2002). "Juvenile idiopathic arthritis. [Danish]." Ugeskrift for Laeger **164**(34): 3941-3946.
- Heubner, G., M. Grosche, et al. (2002). "Therapy of juvenile idiopathic arthritis. [German]." Monatsschrift fur Kinderheilkunde **150**(4): 445-451.
- Horneff, G. (2005). "[Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA)]." Zeitschrift fur Rheumatologie **64**(5): 317-26.
- Horneff, G. (2005). "Treatment of juvenile idiopathic arthritis. [German]." Zeitschrift fur Rheumatologie **64**(5): 317-326.
- Huppertz, H. I. (2002). "Oligoarthritis in children and adolescents. [German]." Monatsschrift fur Kinderheilkunde **150**(4): 437-444.
- Jacobi, A., B. Manger, et al. (2003). "[Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]." Journal der Deutschen Dermatologischen Gesellschaft **1**(4): 259-72.
- Jacobi, A., B. Manger, et al. (2003). "Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders. [German]." Journal der Deutschen Dermatologischen Gesellschaft **1**(4): 259-272.
- Joachim, J., N. Francois, et al. (2005). "Mechanisms and treatment of psoriasis. [French]." Presse Medicale **34**(22 I): 1727-1736.
- Jullien, D. (2006). "Raptiva (efalizumab): A new treatment for psoriasis. [French]." Nouvelles Dermatologiques **25**(4): 264-272.
- Kemeny, L., V. Brodsky, et al. (2006). "[The role of biological drugs in the treatment of psoriasis, results from 9 randomized placebo-controlled trials]." Orvosi Hetilap **147**(21): 981-90.
- Kleinpenning, M. M., G. J. Van Der Wilt, et al. (2005). "Severe psoriasis: Rebound after discontinuation of methotrexate. [Dutch]." Nederlands Tijdschrift voor Dermatologie & Venereologie **15**(5): 242-244.
- Kokelj, F., S. M. Tothova, et al. (2006). "Our experience with etanercept in the treatment of psoriasis." Acta Dermatovenerologica Croatica **14**(4): 241-245.
- Kokelj, F., S. Miertusova Tothova, et al. (2006). "Our experience with etanercept in the treatment of psoriasis." Acta Dermatovenerologica Croatica **14**(4): 241-5.
- Koo, E., V. Brodsky, et al. (2006). "[The role of biological agents in the treatment of psoriatic arthritis, literature review]." Orvosi Hetilap **147**(41): 1963-70.
- Kuiper, L. (2006). "TNF-alpha antagonists. [Dutch]." Geneesmiddelenbulletin **40**(9): 95-103.
- Lapadula, G. (2005). "Biologic therapy with anti-TNFa in spondyloarthritis and other autoimmune diseases. [Italian]." Reumatismo **57**(SUPPL. 4): 22-29.
- Le Thi Huong, D., N. Cassoux, et al. (2007). "Therapy of chronic non infectious uveitis. [French]." Revue de Medecine Interne **28**(4): 232-241.
- Lehnen, M., M. Goos, et al. (2004). "New therapeutic options for psoriatic arthritis: TNF inhibitors. [German]." Deutsche Medizinische Wochenschrift **129**(12): 634-638.
- Lemme, G., A. Campanati, et al. (2007). "Diffuse psoriasis plaque type and infliximab: Our experience and review of literature." Giornale Italiano di Dermatologia e Venereologia **142**(1): 9-14.
- Mahiques Santos, L., T. Martinez-Menchon, et al. (2004). "[Treatment of severe refractory psoriasis with infliximab]. [see comment]." Medicina Clinica **123**(17): 657-8.
- Mahiques Santos, L., T. Martinez-Menchon, et al. (2005). "[Refractory psoriasis treatment with etanercept]." Medicina Clinica **125**(10): 371-3.
- Mahiques Santos, L., T. Martinez-Menchon, et al. (2005). "Refractory psoriasis treatment with etanercept. [Spanish]." Medicina Clinica **125**(10): 371-373.

- Mandl, T. and L. Jacobsson (2002). "[Anti-TNF-alpha treatment--an effective complement in spondyloarthropathy]." Lakartidningen **99**(51-52): 5189-93.
- Mang, R., T. Ruzicka, et al. (2002). "TNF-alpha-antagonists in the therapy of psoriasis - Use and risks. [German]." Zeitschrift fur Hautkrankheiten **77**(11): 548-550.
- Mann, H., R. Becvar, et al. (2006). "Report from the annual Eular congress 2006. [Czech]." Ceska Revmatologie **14**(4): 176-187.
- Marengo de la Fuente, J. L. (2005). "[Applications of monoclonal antibodies and biotechnology products in the treatment of chronic inflammatory diseases]." Revista Clinica Espanola **205**(3): 127-36.
- Marengo de la Fuente, J. L. (2005). "Applications of monoclonal antibodies and biotechnology products in the treatment of chronic inflammatory diseases. [Spanish]." Revista Clinica Espanola **205**(3): 127-136.
- Marquez Saavedra, E. and S. Artacho Criado (2003). "Intensive pharmacosurveillance on infliximab in a general hospital. [Spanish]." Atencion Farmaceutica **5**(3): 136-144.
- Martorell Puigserver, C., J. J. Machi Ribes, et al. (2004). "Evidence of new indications of TNF-a inhibitors. [Spanish]." Atencion Farmaceutica **6**(3): 188-200.
- Moreno Alvarez, P. J. (2004). "International therapeutics: Alefacept. [Spanish]." Farmacia Hospitalaria **28**(5): 388-390.
- Mossner, R. and K. Reich (2005). "[Infliximab. Role in the treatment of psoriasis]." Hautarzt **56**(9): 831-2.
- Mrowietz, U., J. Barth, et al. (2006). "Guideline: Therapy of psoriasis vulgaris with efalizumab. [German]." Journal der Deutschen Dermatologischen Gesellschaft **4**(6): 511-512.
- Muhlhauser, U., F. Munzel, et al. (2003). "[Etanercept]." Deutsche Medizinische Wochenschrift **128**(34-35): 1775-8.
- Musch, A. (2005). "Psoriasis: Promising therapy with immunobiologics?. [German]." Medizinische Monatsschrift fur Pharmazeuten **28**(8): 262-266.
- Neye, H. (2006). "Monoclonal antibodies: Ximab, zumab and umab as drugs. [German]." Pharmazeutische Zeitung **151**(43): 18-28.
- Ortonne, J. P. (2003). "New therapeutics in psoriasis. [French]." Nouvelles Dermatologiques **22**(9 II): 27-29.
- Ortonne, J. P. (2006). "[Remicade in moderate to severe plaque psoriasis]." Annales de Dermatologie et de Venereologie **133**(5 Pt 2): 1S13-7.
- Ortonne, J. P., P. Beaulieu, et al. (2007). "Survey on current management of chronic plaque psoriasis in adult patients by dermatologists. [French]." Nouvelles Dermatologiques **26**(3): 223-224.
- Pavy, S., Y. Allanore, et al. (2005). "Spondylarthropathies and anti-TNFa drugs. [French]." Revue de Medecine Interne **26**(9): 717-724.
- Pay, S. (2006). "The use of anti-TNF drugs in rheumatic disorders: Medical education. [Turkish]." Turkiye Klinikleri Tip Bilimleri Dergisi **26**(4): 430-440.
- Pen-as, P. F. and M. Jones-Caballero (2002). "Monoclonal antibodies in the treatment of psoriasis. [Spanish]." Actas Dermo-Sifiliograficas **93**(6): 355-367.
- Peyri, J. (2003). "Therapeutic and Control Regime of Accute Psoriasis Vulgaris. [Spanish]." Medicina Cutanea Ibero-Latino-Americana **31**(5): 334-336.
- Pezeshki, S., D. J. Pearce, et al. (2004). "Definitions and diagnosis of severe psoriasis: Implications for treatment." Giornale Italiano di Dermatologia e Venereologia **139**(5): 429-438.
- Pfeffer, J., R. Kaufmann, et al. (2006). "Psoriasis SCID-mouse model. [German]." Hautarzt **57**(7): 603-609.
- Pflugbeil, S. and J. Smolen (2004). "Guidelines for starting and continuation of TNF-blocker therapy in patients with chronic inflammatory rheumatic diseases with special regard to Austrian circumstances (national and international consensus findings). [German]." Journal fur Mineralstoffwechsel **11**(4): 50-53.
- Pierard-Franchimont, C. and G. E. Pierard (2006). "[Etanercept (Enbrel) for the treatment of moderate to severe plaque type psoriasis]." Revue Medicale de Liege **61**(3): 201-5.
- Pierard-Franchimont, C. and G. E. Pierard (2006). "Etanercept (Enbrel) for the treatment of moderate to severe plaque type psoriasis. [French]." Revue Medicale de Liege **61**(3): 201-205.

- Pietrzak, A., K. Janowski, et al. (2006). "Psoriasis and heart. Something new under the sun." Giornale Italiano di Dermatologia e Venereologia **141**(5): 457-463.
- Pincelli, C. and A. Giannetti (2006). "Biologicals in the treatment of psoriasis." Giornale Italiano di Dermatologia e Venereologia **141**(4): 371-377.
- Prinz, J. C. (2005). "[Efalizumab. Long-term treatment of psoriasis]." Hautarzt **56**(9): 812-8.
- Prochazkova, L., J. Bohmova, et al. (2006). "Biological treatment of rheumatic diseases. [Czech]." Vnitřní Lékarství **52**(6): 632-639.
- Raffayova, H., J. Rovensky, et al. (2005). "Biological therapy in psoriatic arthritis - Our experience with etanercept. [Slovak]." Rheumatologia **19**(4): 163-167.
- Rioda, W. T. and G. Adorni (2006). "Infliximab treatment in psoriatic arthritis: our experience." Acta Biomedica de l Ateneo Parmense **77**(2): 95-102.
- Rodriguez Moreno, C., P. Lopez Vazquez, et al. (2006). "[Tumor necrosis factor blocking agents: a review. Part I: Clinical efficacy evaluation]." Anales de Medicina Interna **23**(1): 37-45.
- Rodriguez Moreno, C., P. Lopez Vazquez, et al. (2006). "Tumor necrosis factor blocking agents: A review. Part I: Clinical efficacy evaluation. [Spanish]." Anales de Medicina Interna **23**(1): 37-45.
- Rodriguez Moreno, C., P. Lopez Vazquez, et al. (2006). "Tumor necrosis factor blocking agents: A review. Part II: Safety and recommendations. [Spanish]." Anales de Medicina Interna **23**(2): 86-92.
- Romero Crespo, I., R. Anton Torres, et al. (2005). "[Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept]." Farmacia Hospitalaria **29**(3): 171-6.
- Romero Crespo, I., R. Anton Torres, et al. (2005). "Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept. [Spanish]." Farmacia Hospitalaria **29**(3): 171-176.
- Sanmarti Sala, R. (2006). "Adalimumab: New evidence of safety and efficacy in rheumatoid arthritis. [Spanish]." Reumatologia Clinica **2**(SPEC. ISS. 2): 24-27.
- Santos, L. M., T. Martinez-Menchon, et al. (2004). "Treatment of severe refractory psoriasis with infliximab. [Spanish]." Medicina Clinica **123**(17): 657-658.
- Scherer, H. U. and G. R. Burmester (2006). "[Biologicals in the treatment of rheumatic diseases]." Deutsche Medizinische Wochenschrift **131**(41): 2279-85.
- Schmidt, W. A. (2003). "Solutions for off-label therapy. [German]." Zeitschrift fur Rheumatologie Supplement **62**(2): II54-II56.
- Sieper, J. (2002). "[The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court]." Zeitschrift fur Rheumatologie **61**(6): 688-93.
- Sieper, J. and J. Braun (2001). "[Current status of therapeutic approaches in spondyloarthropathies]." Zeitschrift fur Rheumatologie **60**(6): 458-63.
- Sieper, J. and J. Braun (2001). "Treatment options in spondyloarthropathies. [German]." Zeitschrift fur Rheumatologie **60**(6): 458-463.
- Sparsa, A. (2005). "[Etanercept]." Annales de Dermatologie et de Venereologie **132**(11 Pt 1): 861-76.
- Sparsa, A. (2005). "Etanercept. [French]." Annales de Dermatologie et de Venereologie **132**(11 I): 861-876.
- Sterry, W., G. Stingl, et al. (2006). "CLinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from extended treatment in an international, Phase III, placebo-controlled trial. [German, English]." Journal der Deutschen Dermatologischen Gesellschaft **4**(11): 947-957.
- Sterry, W., G. Stingl, et al. (2006). "Clinical Experience Acquired with Raptiva (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from extended treatment in an international, Phase III, placebo-controlled trial." Journal der Deutschen Dermatologischen Gesellschaft **4**(11): 947-56.
- Stolfa, J. (2004). "Treatment of psoriatic arthritis with biological agents. [Czech]." Ceska Revmatologie **12**(4): 175-187.
- Stolfa, J., K. Pavelka, et al. (2005). "Standard recommendations for the management of psoriatic arthritis. [Czech]." Ceska Revmatologie **13**(3): 97-105.
- Strady, C., P. Brochot, et al. (2006). "Tuberculosis during treatment by TNFa-inhibitors. [French]." Presse Medicale **35**(11 II): 1765-1772.

- Strusberg, I., A. M. Bertoli, et al. (2005). "[Use of infliximab in patients of a rheumatologic center]." Medicina **65**(1): 24-30.
- Strusberg, I., A. M. Bertoli, et al. (2005). "Use of infliximab in patients of a rheumatologic center. [Spanish]." Medicina **65**(1): 24-30.
- Throm, S. (2003). "Activities of the CPMP. [German]." Pharmazeutische Industrie **65**(10): 1023-1026.
- Van de Kerkhof, P. C. M. (2003). "If external treatment fails. Psoriasis: Systemic treatment. [Dutch]." Pharmaceutisch Weekblad **138**(14): 482-487.
- Van Den Bosch, F., D. Baeten, et al. (2003). "TNFa blockade with infliximab in patients with active spondyloarthritis. [Dutch]." Tijdschrift voor Geneeskunde **59**(9): 608-613.
- Vena, G. A., N. Cassano, et al. (2006). "Sequential treatment of psoriasis with infliximab followed by cyclosporin: Preliminary results of an open-label prospective study." Giornale Italiano di Dermatologia e Venereologia **141**(3): 221-225.
- Wang, F., W. Lew, et al. (2004). "The therapy of psoriasis based on innate and adaptive immune mechanisms of disease pathogenesis." Giornale Italiano di Dermatologia e Venereologia **139**(3): 207-230.
- Wendling, D., P. Claudepierre, et al. (2003). "[Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies]." Presse Medicale **32**(32): 1517-24.
- Wendling, D., P. Claudepierre, et al. (2003). "Therapeutic use of anti-TNF-a agents in spondyloarthropathies. [French]." Presse Medicale **32**(32): 1517-1524.
- Wetzler, C. (2003). "Psoriasis therapy: Diversion of the immune defence. [German]." Pharmazeutische Zeitung **148**(33): 14-17.
- Wiland, P., J. Szechinski, et al. (2004). "The consensus statement for the use of anti-TNF-alfa agents in patients with psoriatic arthritis. [Polish]." Reumatologia **42**(3): 403-411.
- Williams, J. D. L. and C. E. M. Griffiths (2002). "Cytokine blocking agents in dermatology. [German]." Zeitschrift fur Hautkrankheiten **77**(12): 663-668.
- Wozel, G. (2005). "[Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis]." Hautarzt **56**(9): 819-30.
- Wozel, G. (2005). "Etanercept. An effective TNF a-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis. [German]." Hautarzt **56**(9): 819-830.
- Young, H. S. and C. E. M. Griffiths (2003). "Advances in immunotherapy for psoriasis." Giornale Italiano di Dermatologia e Venereologia **138**(5): 349-354.

Excluded Conference Papers (n=63)

- Alavi, A. and J. S. Axford (2006). "Current concepts in rheumatology, royal society of medicine." Expert Review of Clinical Immunology **2**(2): 189-192.
- Anandarajah, A. P. and C. T. Ritchlin (2004). "Treatment update on spondyloarthritis: From NSAIDs and DMARDs to anti-TNF-a agents." Postgraduate Medicine **116**(5): 31-40.
- Anderson, P. J. (2005). "Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles." Seminars in Arthritis & Rheumatism **34**(5 SUPPL.): 19-22.
- Atzeni, F., M. Turiel, et al. (2005). "Autoimmunity and anti-TNF-a agents." Annals of the New York Academy of Sciences **1051**(pp 559-569).
- Babich, M. (2006). "IUPHAR 2006 - 15th World Congress of Pharmacology. Antibody-based therapies and diagnostics. 2-7 July 2006, Beijing, China." Idrugs **9**(9): 600-603.
- Birnie, A., S. Langan, et al. (2007). "Updates from the British association of dermatologists 86th annual meeting, 4-7 July 2006, Manchester, U.K." British Journal of Dermatology **156**(5): 802-813.
- Borchardt, J. K. (2004). "Focus on small molecule inhibitors for treatment of inflammatory and autoimmune diseases." Drug News & Perspectives **17**(9): 607-614.
- Braddock, M. (2003). "Inflammation in drug discovery and development - SRI's Seventh International Meeting 20-21 February 2003, San Diego, USA." Idrugs **6**(4): 318-322.
- Braddock, M. (2005). "Anti-arthritis therapies 2005. 23-24 February 2005, London, UK." Idrugs **8**(4): 288-289.
- Braddock, M. (2005). "AntiArthritis therapies 2005." Expert Opinion on Investigational Drugs **14**(4): 539-543.

- Braun, J. and J. Sieper (2002). "Building consensus on nomenclature and disease classification for ankylosing spondylitis: Results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002." Annals of the Rheumatic Diseases **61**(SUPPL. 3): iii61-iii67.
- Braun, J., J. Xiang, et al. (2000). "Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: First clinical and laboratory experiences." Annals of the Rheumatic Diseases **59**(SUPPL. 1): i85-i89.
- Camp, R. D. R. (2003). "Updates from the Third International Congress on Psoriasis: From Gene to Clinic, the Royal College of Physicians, London, U.K., 21-23 November 2002." British Journal of Dermatology **148**(5): 878-884.
- Chan, P. T. (2005). "Shaping the management of psoriasis." Hong Kong Dermatology & Venereology Bulletin **13**(1): 41-42.
- Christina Kim, E. and C. Stephen Foster (2006). "Immunomodulatory therapy for the treatment of ocular inflammatory disease: Evidence-based medicine recommendations for use." International Ophthalmology Clinics **46**(2): 141-164.
- Cohen, M. D. (2004). "Raising expectations for arthritis treatment: Biologic response modifiers are making remission possible." Postgraduate Medicine **116**(5): 41-42+48-50.
- Cush, J. J. (2005). "Biological drug use: US perspectives on indications and monitoring." Annals of the Rheumatic Diseases **64**(SUPPL. 4): iv18-iv23.
- Cutler, A. and F. Brombacher (2005). "Cytokine therapy." Annals of the New York Academy of Sciences **1056**(pp 16-29).
- Dedrick, R. L., P. Walicke, et al. (2001). "Anti-adhesion antibodies Efalizumab, a humanized anti-CD11a monoclonal antibody." Transplant Immunology **9**(2-4): 181-186.
- Feldman, S. R. and G. G. Krueger (2005). "Psoriasis assessment tools in clinical trials." Annals of the Rheumatic Diseases **64**(SUPPL. 2): ii65-ii68.
- Ferrer, E. (2006). "Emerging therapeutic strategies for chronic inflammatory diseases." Drug News & Perspectives **19**(6): 353-358.
- Furst, D. E., F. C. Breedveld, et al. (2004). "Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNFa) blocking agents and interleukin-1 receptor antagonist (IL-1 ra), for the treatment of rheumatic diseases, 2004." Annals of the Rheumatic Diseases **63**(SUPPL. 2): ii2-ii12.
- Furst, D. E., F. C. Breedveld, et al. (2005). "Updated consensus statement on biological agents, specifically tumour necrosis factor a (TNFa) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005." Annals of the Rheumatic Diseases **64**(SUPPL. 4): iv2-iv14.
- Furst, D. E., F. C. Breedveld, et al. (2006). "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006." Annals of the Rheumatic Diseases **65**(SUPPL. 3): iii2-iii15.
- Gladman, D. D., P. J. Mease, et al. (2005). "Outcome measures in psoriatic arthritis." Journal of Rheumatology **32**(11): 2262-2269.
- Gladman, D. D., V. Strand, et al. (2005). "OMERACT 7 psoriatic arthritis workshop: Synopsis." Annals of the Rheumatic Diseases **64**(SUPPL. 2): ii115-ii116.
- Gottlieb, A. B. (2004). "Novel Immunotherapies for Psoriasis: Clinical Research Delivers New Hope for Patients and Scientific Advances." Journal of Investigative Dermatology. Symposium Proceedings **9**(1): 79-83.
- Goupille, P. (2005). "Psoriatic arthritis." Joint, Bone, Spine: Revue du Rhumatisme **72**(6): 466-470.
- Griffiths, R. and K. Koch (2002). "New drugs for the treatment of inflammatory, respiratory and immunological diseases." Inflammation Research **51**(2): 77-79.
- Groves, R. (2004). "Cytokine and anti-cytokine therapy in the treatment of inflammatory skin disease." Cytokine **28**(4-5): 162-166.
- Haraoui, B. (2005). "Differentiating the efficacy of the tumor necrosis factor inhibitors." Seminars in Arthritis & Rheumatism **34**(5 SUPPL.): 7-11.

- Haraoui, B. (2005). "Differentiating the efficacy of tumor necrosis factor inhibitors." Journal of Rheumatology **32**(SUPPL. 74): 3-7.
- Kansky, A. (2004). "34th Annual Meeting of the European Society for Dermatological Research: Vienna, September 9-11, 2004." Acta Dermatovenerologica Alpina, Pannonica et Adriatica **13**(4): 139-141.
- Kapadia, M. K. and P. A. D. Rubin (2006). "The emerging use of TNF-a inhibitors in orbital inflammatory disease." International Ophthalmology Clinics **46**(2): 165-181.
- Korstanje, C. (2004). "European Society for Dermatological Research - 34th Annual Meeting. 9-11 September 2004, Vienna, Austria." Idrugs **7**(11): 994-995.
- Labro, M. T. (2005). "Biotechnology - Fourth Croatian International Scientific Conference. Biotechnology and immunomodulatory drugs. 20-23 February 2005, Zagreb, Croatia." Idrugs **8**(4): 290-293.
- Levy, R. A., C. Galarza, et al. (2004). "I Latin American Congress of Autoimmunity Galapagos - September 15-18." Autoimmunity Reviews **3**(1): 76-87.
- Maini, R. N. (2005). "The 2005 International Symposium on Advances in Targeted Therapies: What have we learned in the 2000s and where are we going?" Annals of the Rheumatic Diseases **64**(SUPPL. 4): iv106-iv108.
- McMichael, A. J. (2003). "The new biologics in psoriasis: Possible treatments for alopecia areata." Journal of Investigative Dermatology. Symposium Proceedings **8**(2): 217-218.
- Mease, P. (2006). "Psoriatic arthritis update." Bulletin - Hospital for Joint Diseases **64**(1-2): 25-31.
- Mease, P. J., C. E. Antoni, et al. (2005). "Psoriatic arthritis assessment tools in clinical trials." Annals of the Rheumatic Diseases **64**(SUPPL. 2): ii49-ii54.
- Mease, P. J., F. Behrens, et al. (2005). "Discussion: Assessment of psoriatic arthritis." Annals of the Rheumatic Diseases **64**(SUPPL. 2): ii69-ii73.
- Mease, P. J., W. H. Boehncke, et al. (2005). "Discussion: Treatment of psoriatic arthritis and psoriasis." Annals of the Rheumatic Diseases **64**(SUPPL. 2): ii91-ii92.
- Mehrabi, D., J. B. DiCarlo, et al. (2002). "Advances in the management of psoriasis: Monoclonal antibody therapies." International Journal of Dermatology **41**(12): 827-835.
- Moreland, L. W. (2004). "Biologic therapies on the horizon for rheumatoid arthritis." JCR: Journal of Clinical Rheumatology **10**(3 SUPPL.): S32-S39.
- Nestorov, I. (2005). "Clinical pharmacokinetics of TNF antagonists: How do they differ?" Seminars in Arthritis & Rheumatism **34**(5 SUPPL.): 12-18.
- Nestorov, I. (2005). "Clinical pharmacokinetics of tumor necrosis factor antagonists." Journal of Rheumatology **32**(SUPPL. 74): 13-18.
- Ortonne, J. P. (2006). "A paradigm for the systemic treatment of plaque psoriasis." Journal of the European Academy of Dermatology & Venereology **20**(SUPPL. 2): 77-79.
- Rao, U. R. K. and F. Fatima (2004). "Biological response modifiers." APLAR Journal of Rheumatology **7**(2): 179-183.
- Reimold, A. M. (2003). "New indications for treatment of chronic inflammation by TNF-a blockade." American Journal of the Medical Sciences **325**(2): 75-92.
- Scheuerbrandt, G. (2006). "Approaching therapies for boys with Duchenne muscular dystrophy. Parent Project Muscular Dystrophy. Annual Conference in Cincinnati/Ohio, 13-16 July 2006." Acta Myologica **25**(2): 77-97.
- Sibilia, J. (2006). "Psoriasis: Skin and joints, same fight?" Journal of the European Academy of Dermatology & Venereology **20**(SUPPL. 2): 56-72.
- Skurkovich, S. and B. Skurkovich (2005). "Anticytokine therapy, especially anti-interferon-gamma, as a pathogenetic treatment in TH-1 autoimmune diseases." Annals of the New York Academy of Sciences **1051**(pp 684-700).
- Sterry, W. (2004). "Foreword: The value of biological therapies for psoriasis management." British Journal of Dermatology, Supplement **151**(69): 1.
- Sterry, W., J. Barker, et al. (2004). "Biological therapies in the systemic management of psoriasis: International Consensus Conference." British Journal of Dermatology, Supplement **151**(69): 3-17.

- Stone, J. H. (2003). "Current status of tumor necrosis factor inhibition strategies in the treatment of vasculitis." Kidney & Blood Pressure Research **26**(4): 240-248.
- Tayton-Martin, H. "Resurgent, refocused and on the threshold insights from Ernst & Young's 11th annual global biotechnology reports." Journal.
- Tremaine, W. J. (1999). "The medical treatment of active Crohn's disease." Drugs of Today **35**(SUPPL. A): 89-96.
- Tubach, F., D. Salmon-Ceron, et al. (2005). "The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFa therapy." Joint, Bone, Spine: Revue du Rhumatisme **72**(6): 456-460.
- Vasoo, S. and G. R. V. Hughes (2005). "Theory, targets and therapy in systemic lupus erythematosus." Lupus **14**(3): 181-188.
- Veale, D. J., C. Ritchlin, et al. (2005). "Immunopathology of psoriasis and psoriatic arthritis." Annals of the Rheumatic Diseases **64**(SUPPL. 2): ii26-ii29.
- White, B. (2002). "International Society for Rheumatic Therapy guest society symposium: Recent therapeutic experiences with new generation drugs for inflammatory diseases." Inflammation Research **51**(2): 73-75.
- Winterfield, L. S., A. Menter, et al. (2005). "Psoriasis treatment: Current and emerging directed therapies." Annals of the Rheumatic Diseases **64**(SUPPL. 2): ii87-ii90.

Excluded Short Surveys (n=18)

- Al-Ratrou, J. (2005). "New drugs in the management of psoriasis." Bahrain Medical Bulletin **27**(2): 89-90.
- Anonymous (2001). "Editorial comments." Journal of the American Osteopathic Association **101**(8): 481-482.
- Cowden, J. and S. K. Parker (2006). "Monoclonal antibodies: Production, uses and side effects." Pediatric Infectious Disease Journal **25**(6): 553-555.
- Dinarello, C. A. (2003). "Setting the cytokine trap for autoimmunity." Nature Medicine **9**(1): 20-22.
- Dumont, F. J. (2004). "Technology evaluation: Abatacept, Bristol-Myers Squibb." Current Opinion in Molecular Therapeutics **6**(3): 318-330.
- Gebhart, F. (2001). "Two biotech companies lead attack on psoriasis." Drug Topics **145**(14): 16.
- Jordan, A. and J. E. McDonagh (2006). "Juvenile idiopathic arthritis: The paediatric perspective." Pediatric Radiology **36**(8): 734-742.
- Kaneider, N. C., A. J. Leger, et al. (2006). "Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions." FEBS Journal **273**(19): 4416-4424.
- Lebwohl, M. (2004). "Innovations in the treatment of psoriasis." Journal of the American Academy of Dermatology **51**(1 SUPPL.): S40-S41.
- Mease, P. (2004). "TNFa therapy in psoriatic arthritis and psoriasis." Annals of the Rheumatic Diseases **63**(7): 755-758.
- Murff, H. J. (2006). "Etanercept improves skin lesions and symptoms of depression and fatigue in patients with moderate to severe psoriasis." Journal of Clinical Outcomes Management **13**(3): 135-136.
- Nash, P. (2006). "Alefcept plus methotrexate for psoriatic arthritis: Commentary." Nature Clinical Practice Rheumatology **2**(9): 470-471.
- Nicolls, M. R. and R. G. Gill (2006). "LFA-1 (CD11a) as a therapeutic target." American Journal of Transplantation **6**(1): 27-36.
- Papp, K. A. (2006). "The long-term efficacy and safety of new biological therapies for psoriasis." Archives of Dermatological Research **298**(1): 7-15.
- Reichert, J. M. (2004). "Trends in the development of therapeutic anti-cytokine antibodies." Drug Discovery Today **9**(8): 348.
- Ritchlin, C. (2006). "Efficacy and safety of infliximab for the treatment of psoriatic arthritis: Commentary." Nature Clinical Practice Rheumatology **2**(6): 300-301.
- Rothe, M. J. and C. Grin (2003). "Psoriasis therapy: What's new." Consultant **43**(7): 890-891.
- Walsh, G. (2006). "Biopharmaceutical benchmarks 2006." Nature Biotechnology **24**(7): 769-776.

Review papers Scanned for new RCTs (n=2)

- Boehncke, W. H., J. Prinz, et al. (2006). "Biologic therapies for psoriasis. A systematic review." Journal of Rheumatology **33**(7): 1447-1451.
- Smith, C. H., A. V. Anstey, et al. (2005). "British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005." British Journal of Dermatology **153**(3): 486-497.
- Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46).

Excluded Reviews

Not Adult Plaque Psoriasis Therapy (n=257)

- Aberra, F. N. and G. R. Lichtenstein (2006). "Infliximab in Ulcerative Colitis." Gastroenterology Clinics of North America **35**(4): 821-836.
- Abramson, S. B. and Y. Yazici (2006). "Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis." Advanced Drug Delivery Reviews **58**(2): 212-225.
- Abuzakouk, M., C. Feighery, et al. (2002). "Tumour necrosis factor blocking agents: A new therapeutic modality for inflammatory disorders." British Journal of Biomedical Science **59**(3): 173-179.
- Alazemi, S. and M. A. Campos (2006). "Interferon-induced sarcoidosis." International Journal of Clinical Practice **60**(2): 201-211.
- Aletaha, D. and J. S. Smolen (2006). "The definition and measurement of disease modification in inflammatory rheumatic diseases." Rheumatic Diseases Clinics of North America **32**(1): 9-44.
- Ancowitz, B. and S. A. Shah (2006). "Infusion Services in the Gastroenterology Practice." Gastrointestinal Endoscopy Clinics of North America **16**(4): 727-742.
- Anonymous (2006). "Use NSAIDs to relieve pain and stiffness in patients with ankylosing spondylitis and reserve tumour necrosis factor- α antagonists for NSAID-refractory patients." Drugs & Therapy Perspectives **22**(5): 11-14.
- Arend, S. M., F. C. Breedveld, et al. (2003). "TNF- α blockade and tuberculosis: Better look before you leap." Netherlands Journal of Medicine **61**(4): 111-119.
- Arkfeld, D. G. and E. Rubenstein (2005). "Quest for the Holy Grail to cure arthritis and osteoporosis: Emphasis on bone drug delivery systems." Advanced Drug Delivery Reviews **57**(7): 939-944.
- Aruffo, A. and D. Hollenbaugh (2001). "Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease." Current Opinion in Immunology **13**(6): 683-686.
- Atthobari, J., J. M. Bos, et al. (2005). "Adherence of pharmaco-economic studies to national guidelines in the Netherlands." Pharmacy World & Science **27**(5): 364-370.
- Baeten, D. (2006). "Infliximab: A chimeric anti-TNF- α monoclonal antibody for the treatment of ankylosing spondylitis and other spondyloarthritides." Therapy **3**(2): 191-200.
- Baeten, D. and F. De Keyser (2004). "The histopathology of spondyloarthropathy." Current Molecular Medicine **4**(1): 1-12.
- Baker, D. E. (2006). "New drugs approved by the FDA new dosage forms and indications agents pending FDA approval significant labeling changes." Hospital Pharmacy **41**(11): 1086-1089.
- Bendas, G. (2005). "Inhibitors of membrane receptors involved in leukocyte extravasation." Mini-Reviews in Medicinal Chemistry **5**(6): 575-584.
- Benson, E. M. (2004). "Immunologic manipulation for the threatened fetus." Thrombosis Research **114**(5-6 SPEC. ISS.): 427-434.
- Biancone, L., E. Calabrese, et al. (2007). "Treatment with biologic therapies and the risk of cancer in patients with IBD." Nature Clinical Practice Gastroenterology & Hepatology **4**(2): 78-91.
- Blonski, W. and G. R. Lichtenstein (2006). "Complications of biological therapy for inflammatory bowel diseases." Current Opinion in Gastroenterology **22**(1): 30-43.
- Bluestone, J. A., E. W. St Clair, et al. (2006). "CTLA4Ig: Bridging the basic immunology with clinical application." Immunity **24**(3): 233-238.

- Booth, A. D., J. D. Firth, et al. (2003). "Immunotherapy for autoimmune and inflammatory renal diseases." Expert Opinion on Biological Therapy 3(3): 487-500.
- Bratcher, J. M. and B. I. Korelitz (2006). "Toxicity of infliximab in the course of treatment of Crohn's disease." Expert Opinion on Drug Safety 5(1): 9-16.
- Braun, F. and M. Behrend (2006). "Basic immunosuppressive drugs outside solid organ transplantation." Expert Opinion on Investigational Drugs 15(3): 267-291.
- Braun, J. and J. Sieper (2002). "Therapy of ankylosing spondylitis and other spondyloarthritides: Established medical treatment, anti-TNF- α therapy and other novel approaches." Arthritis Research 4(5): 307-321.
- Braun, J. and J. Sieper (2003). "Role of novel biological therapies in psoriatic arthritis: Effects on joints and skin." Biodrugs 17(3): 187-199.
- Braun, J. and J. Sieper (2004). "Biological therapies in the spondyloarthritides - The current state." Rheumatology 43(9): 1072-1084.
- Braun, J., F. De Keyser, et al. (2001). "New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy." Current Opinion in Rheumatology 13(4): 245-249.
- Brown, M. A. (2005). "Antibody treatments of inflammatory arthritis." Current Medicinal Chemistry 12(25): 2943-2946.
- Bukulmez, H. and R. A. Colbert (2002). "Juvenile spondyloarthropathies and related arthritis." Current Opinion in Rheumatology 14(5): 531-535.
- Burgos-Vargas, R., C. Pacheco-Tena, et al. (2002). "The juvenile-onset spondyloarthritides: Rationale for clinical evaluation." Best Practice & Research in Clinical Rheumatology 16(4): 551-572.
- Burrill, G. S. (2003). "Biotech endures: Looking back at 2002 and ahead to 2003." Journal of Biolaw & Business 6(1): 82-86.
- Callen, J. P. (2006). "Cutaneous lupus erythematosus: A personal approach to management." Australasian Journal of Dermatology 47(1): 13-27.
- Cassell, S. and A. F. Kavanaugh (2006). "Therapies for psoriatic nail disease. A systematic review." Journal of Rheumatology 33(7): 1452-1456.
- Cassell, S. and A. Kavanaugh "Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment." Journal.
- Chan, E. S. L., P. Fernandez, et al. (2007). "Methotrexate in rheumatoid arthritis." Expert Review of Clinical Immunology 3(1): 27-33.
- Chang, J. H., P. J. McCluskey, et al. (2005). "Acute anterior uveitis and HLA-B27." Survey of Ophthalmology 50(4): 364-388.
- Chartier-Kastler, E. and K. Davidson (2007). "Evaluation of Quality of Life and Quality of Sleep in Clinical Practice{A figure is presented}." European Urology Supplements 6(9): 576-584.
- Chatenoud, L. (2006). "Immune therapies of autoimmune diseases: are we approaching a real cure?" Current Opinion in Immunology 18(6): 710-717.
- Chira, P. and C. I. Sandborg (2003). "Novel therapies in pediatric rheumatic diseases." Current Opinion in Pediatrics 15(6): 579-585.
- Choo-Kang, B. S. W., S. Hutchison, et al. (2005). "TNF-blocking therapies: An alternative mode of action?" Trends in Immunology 26(10): 518-522.
- Cockcroft, D. W. (2004). "Recombinant therapies in asthma." Allergy Asthma & Clinical Immunology 1(1): 34-41.
- Cohen, M. D. (2002). "The use of TNF antagonists in rheumatic diseases other than rheumatoid arthritis." Bulletin on the Rheumatic Diseases 51(12).
- Cohen, M., T. Morrow, et al. (2006). "Managing the expanded use of biologics across therapeutic areas: An example from B-cell targeted therapies." American Journal of Managed Care 12(SUPPL. 2): S24-S37.
- Cohen, S. P. (2005). "Sacroiliac joint pain: A comprehensive review of anatomy, diagnosis and treatment." Anesthesia & Analgesia 101(5): 1440-1453.

- Cornelis, S., K. Kersse, et al. (2007). "Inflammatory caspases: Targets for novel therapies." Current Pharmaceutical Design **13**(4): 367-385.
- Criscione, L. G. and E. W. St Clair (2002). "Tumor necrosis factor- α antagonists for the treatment of rheumatic diseases." Current Opinion in Rheumatology **14**(3): 204-211.
- Cuchacovich, R. (2006). "Clinical Applications of the Polymerase Chain Reaction: An Update." Infectious Disease Clinics of North America **20**(4): 735-758.
- Cummins, C., M. Connock, et al. (2002). "A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: Etanercept." Health Technology Assessment (Winchester, England) **6**(17).
- Cush, J., R. I. Fox, et al. (2003). "Rheumatoid Arthritis: Current Perspectives on DMARD Therapy." Medical Crossfire **5**(8): 27-45+48.
- Danese, S., S. Semeraro, et al. (2005). "Extraintestinal manifestation in inflammatory bowel disease." World Journal of Gastroenterology **11**(46): 7227-7236.
- Das, A. M., D. E. Griswold, et al. (2006). "Biopharmaceutical therapeutics for asthma remodeling." Current Pharmaceutical Design **12**(25): 3233-3240.
- De Boer, W. I. (2005). "Perspectives for cytokine antagonist therapy in COPD." Drug Discovery Today **10**(2): 93-106.
- De Keyser, F., D. Baeten, et al. (2004). "Structure-modifying capacity of anti-tumour necrosis factor- α therapy in ankylosing spondylitis." Drugs **64**(24): 2793-2811.
- De Keyser, F., H. Mielants, et al. (2001). "Current use of biologicals for the treatment of spondyloarthropathies." Expert Opinion on Pharmacotherapy **2**(1): 85-93.
- Deepe Jr, G. S. and R. S. Wallis (2006). "Tumor necrosis factor- α inhibitors and granulomatous infectious." Drug Discovery Today: Disease Mechanisms **3**(2): 295-300.
- Dinarello, C. A. (2006). "The paradox of pro-inflammatory cytokines in cancer." Cancer & Metastasis Reviews **25**(3): 307-313.
- Dong, X. and D. Fetterolf (2005). "Specialty pharmacy: An emerging area of interest for medical management." Disease Management **8**(2): 73-85.
- Dumont, F. J. (2004). "CTLA4-Ig fusion proteins: Promise for improved therapy of transplant rejection and autoimmune diseases." Therapy **1**(2): 289-304.
- Dumont, F. J. (2005). "Fontolizumab Protein Design Labs." Current Opinion in Investigational Drugs **6**(5): 537-544.
- Efthimiou, P. and J. A. Markenson (2005). "Role of biological agents in immune-mediated inflammatory diseases." Southern Medical Journal **98**(2): 192-204.
- Ellerin, T., R. H. Rubin, et al. (2003). "Infections and Anti-Tumor Necrosis Factor α Therapy." Arthritis & Rheumatism **48**(11): 3013-3022.
- Emery, P. (2003). "The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis." Expert Opinion on Investigational Drugs **12**(4): 673-681.
- Fan, P. T. and K. H. Leong (2007). "The use of biological agents in the treatment of rheumatoid arthritis." Annals of the Academy of Medicine, Singapore **36**(2): 128-134.
- Ferre, N. and J. Claria (2006). "New insights into the regulation of liver inflammation and oxidative stress." Mini-Reviews in Medicinal Chemistry **6**(12): 1321-1330.
- Finucane, K. A. and C. B. Archer (2005). "Recent advances in rheumatology: Biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus." Clinical & Experimental Dermatology **30**(2): 201-204.
- FitzGerald, O. and I. McInnes (2006). "Spondyloarthropathy: disease at the crossroads of immunity." Best Practice & Research in Clinical Rheumatology **20**(5): 949-967.
- Foeldvari, I. and A. Wierk (2005). "Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis." Journal of Rheumatology **32**(2): 362-365.
- Foster, H. and K. Khawaja (2005). "When to request a paediatric rheumatology opinion." Current Paediatrics **15**(1): 1-8.

- Fox, R. and S. Helfgott (2004). "Leflunomide in the treatment of rheumatoid arthritis and other autoimmune disorders." APLAR Journal of Rheumatology 7(1): 71-78.
- Garber, K. (2004). "Make or break for costimulatory blockers." Nature Biotechnology 22(2): 145-147.
- Gardner, G. C. (2005). "Inflammatory arthritis in the era of the biologics." Clinical & Applied Immunology Reviews 5(1): 19-44.
- Genovese, M. C. (2005). "Biologic therapies in clinical development for the treatment of rheumatoid arthritis." JCR: Journal of Clinical Rheumatology 11(3 SUPPL.): S45-S54.
- Genovese, M. C. and J. M. Kremer (2004). "Treatment of rheumatoid arthritis with etanercept." Rheumatic Diseases Clinics of North America 30(2): 311-328.
- Gilroy, D. W. (2004). "The endogenous control of acute inflammation - From onset to resolution." Drug Discovery Today: Therapeutic Strategies 1(3): 313-319.
- Gladman, D. D. (2005). "Traditional and newer therapeutic options for psoriatic arthritis: An evidence-based review." Drugs 65(9): 1223-1238.
- Gladman, D. D., P. Helliwell, et al. (2004). "Assessment of Patients with Psoriatic Arthritis: A Review of Currently Available Measures." Arthritis & Rheumatism 50(1): 24-35.
- Goldmuntz, E. A. and P. H. White (2006). "Juvenile idiopathic arthritis: A review for the pediatrician." Pediatrics in Review 27(4): e24-e32.
- Gonzalez-Amaro, R., M. Mittelbrunn, et al. (2005). "Therapeutic anti-integrin (a4 and aL) monoclonal antibodies: Two-edged swords?" Immunology 116(3): 289-296.
- Green, C. (2002). "New drugs in the treatment of rheumatoid arthritis." Hospital Pharmacist 9(1): 16-19.
- Green, D. R. and G. Kroemer (2005). "Pharmacological manipulation of cell death: Clinical applications in sight?" Journal of Clinical Investigation 115(10): 2610-2617.
- Hamilton, J. and H. Capell (2001). "The treatment of juvenile arthritis." Expert Opinion on Pharmacotherapy 2(7): 1085-1092.
- Haraoui, B. and E. Keystone (2006). "Musculoskeletal manifestations and autoimmune diseases related to new biologic agents." Current Opinion in Rheumatology 18(1): 96-100.
- Hasler, P. (2006). "Biological therapies directed against cells in autoimmune disease." Springer Seminars in Immunopathology 27(4): 443-456.
- Hedrich, O., J. Finley, et al. (2005). "Novel Neurohormonal Antagonist Strategies: Vasopressin Antagonism, Anticytokine Therapy, and Endothelin Antagonism in Patients Who Have Heart Failure." Heart Failure Clinics 1(1): 103-127.
- Helliwell, P. S. (2006). "Therapies for dactylitis in psoriatic arthritis. A systematic review." Journal of Rheumatology 33(7): 1439-1441.
- Holden, W., T. Orchard, et al. (2003). "Enteropathic arthritis." Rheumatic Diseases Clinics of North America 29(3): 513-530.
- Hsia, E. C., K. M. Ruley, et al. (2006). "Infliximab (Remicade): From bench to clinical practice. A paradigm shift in rheumatology practice." APLAR Journal of Rheumatology 9(2): 107-118.
- Hudson, P. J. and C. Souriau (2003). "Engineered antibodies." Nature Medicine 9(1): 129-134.
- Husted, T. L. and A. B. Lentsch (2005). "Anti-inflammatory approaches to the prevention of ischemia/reperfusion injury in solid organ transplantation." Current Opinion in Investigational Drugs 6(5): 508-512.
- Johnston, S. L. (2007). "Biologic therapies: What and when?" Journal of Clinical Pathology 60(1): 8-17.
- Jois, S. D. S., L. Jining, et al. (2006). "Targeting t-cell adhesion molecules for drug design." Current Pharmaceutical Design 12(22): 2797-2812.
- Kataria, R. K. and L. H. Brent (2004). "Spondyloarthropathies." American Family Physician 69(12): 2853-2860.
- Kavanaugh, A. (2007). "Economic issues with new rheumatologic therapeutics." Current Opinion in Rheumatology 19(3): 272-276.
- Kavanaugh, A. F., C. T. Ritchlin, et al. (2006). "Systematic review of treatments for psoriatic arthritis: An evidence based approach and basis for treatment guidelines." Journal of Rheumatology 33(7): 1417-1421.

- Khan, M. A. (2002). "Update on spondyloarthropathies." Annals of Internal Medicine **136**(12): 896-907.
- Khanna, D., M. McMahon, et al. (2004). "Safety of tumour necrosis factor- α antagonists." Drug Safety **27**(5): 307-324.
- Kiratisavee, S. and L. H. Brent (2004). "Spondyloarthropathies: Using presentation to make the diagnosis." Cleveland Clinic Journal of Medicine **71**(3): 184-206.
- Kirou, K. A., J. E. Salmon, et al. (2006). "Soluble mediators as therapeutic targets in systemic lupus erythematosus: Cytokines, immunoglobulin receptors, and the complement system." Rheumatic Diseases Clinics of North America **32**(1): 103-119.
- Kleinschnitz, C., S. G. Meuth, et al. (2007). "Immunotherapeutic approaches in MS: Update on pathophysiology and emerging agents or strategies 2006." Endocrine, Metabolic & Immune Disorders Drug Targets **7**(1): 35-63.
- Kohl, J. (2006). "Drug evaluation: The C5a receptor antagonist PMX-53." Current Opinion in Molecular Therapeutics **8**(6): 529-538.
- Kong, J. S. W., S. S. Teuber, et al. (2006). "Potential adverse events with biologic response modifiers." Autoimmunity Reviews **5**(7): 471-485.
- Krueger, G. G. (2002). "Clinical features of psoriatic arthritis." American Journal of Managed Care **8**(6 SUPPL.): S160-S170.
- Kuehn, B. M. (2005). "Pharmaceutical industry funding for residencies sparks controversy." Jama **293**(13): 1572+1579-1580.
- Kuek, A., B. L. Hazleman, et al. (2007). "Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: A medical revolution." Postgraduate Medical Journal **83**(978): 251-260.
- Kumar, A. and R. Grover (2004). "Biological therapies for rheumatic disorders." Journal International Medical Sciences Academy **17**(2): 142-146.
- Kwon, J. H. and R. J. Farrell (2005). "The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents." Critical Reviews in Oncology-Hematology **56**(1 SPEC. ISS.): 169-178.
- Laffly, E. and R. Sodoyer (2005). "Monoclonal and recombinant antibodies, 30 years after." Human Antibodies **14**(1-2): 33-55.
- Lawry, M. (2007). "Biological therapy and nail psoriasis." Dermatologic Therapy **20**(1): 60-67.
- Lee, A. T. Y. and K. Pile (2003). "Disease modifying drugs in adult rheumatoid arthritis." Australian Prescriber **26**(2): 36-40.
- Lee, E. and A. A. Sinha (2005). "T cell targeted immunotherapy for autoimmune disease." Autoimmunity **38**(8): 577-596.
- Lee, H. J. and A. A. Sinha (2006). "Cutaneous lupus erythematosus: Understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies." Autoimmunity **39**(6): 433-444.
- Lele, R. D. (2005). "Indian biotechnology: Challenges and opportunities - A clinician's perspective." Indian Journal of Biotechnology **4**(1): 9-20.
- Leung, Y., L. Tam, et al. (2007). "Psoriatic arthritis as a distinct disease entity." Journal of Postgraduate Medicine **53**(1): 63-71.
- Lewkowicz, D. and A. B. Gottlieb (2004). "Pediatric psoriasis and psoriatic arthritis." Dermatologic Therapy **17**(5): 364-375.
- Lim, L., E. B. Suhler, et al. (2006). "Biologic therapies for inflammatory eye disease." Clinical & Experimental Ophthalmology **34**(4): 365-374.
- Liossis, S. N. and G. C. Tsokos (2005). "Monoclonal antibodies and fusion proteins in medicine." Journal of Allergy & Clinical Immunology **116**(4): 721-729.
- Lipsy, R. J. (2002). "Etanercept and its implications for managed care." American Journal of Managed Care **8**(6 SUPPL.): S194-S200.
- Liu, Y., D. Cortinovis, et al. (2004). "Recent advances in the treatment of the spondyloarthropathies." Current Opinion in Rheumatology **16**(4): 357-365.

- Lorenz, H. M. (2000). "TNF inhibitors in the treatment of arthritis." Current Opinion in Investigational Drugs **1**(2): 188-193.
- Lu, T.-T. and C. Hill (2006). "Managing patients taking tumour necrosis factor inhibitors." Australian Prescriber **29**(3): 67-70.
- Lutters, B. C. H., M. A. Leeuwenburgh, et al. (2004). "Blocking endothelial adhesion molecules: A potential therapeutic strategy to combat atherogenesis." Current Opinion in Lipidology **15**(5): 545-552.
- Maini, R. (2004). "Infliximab treatment of rheumatoid arthritis." Rheumatic Diseases Clinics of North America **30**(2): 329-347.
- Manadan, A. M., W. Sequeira, et al. (2006). "The treatment of psoriatic arthritis." American Journal of Therapeutics **13**(1): 72-79.
- Mariette, X. (2004). "Emerging biological therapies in rheumatoid arthritis." Joint, Bone, Spine: Revue du Rhumatisme **71**(6): 470-474.
- Martin, J. J. (2005). "Tumor necrosis factor inhibitors and methotrexate: Implications for deployed personnel." Aviation Space & Environmental Medicine **76**(12): 1162-1166.
- Martin, T. M., J. R. Smith, et al. (2002). "Anterior uveitis: Current concepts of pathogenesis and interactions with the spondyloarthropathies." Current Opinion in Rheumatology **14**(4): 337-341.
- Martino, G., L. Adorini, et al. (2002). "Inflammation in multiple sclerosis: The good, the bad, and the complex." Lancet Neurology **1**(8): 499-509.
- Marzo-Ortega, H., L. Cawkwell, et al. (2005). "Early oligoarthritis." Rheumatic Diseases Clinics of North America **31**(4): 627-639.
- Mascelli, M. A., H. Zhou, et al. (2007). "Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development." Journal of Clinical Pharmacology **47**(5): 553-565.
- Mealy, N. E. and B. Lupone (2006). "Drugs under development for the treatment of ophthalmic disorders." Drugs of the Future **31**(7): 645-659.
- Mease, P. (2003). "Advances in the treatment of psoriatic arthritis." Drug Benefit Trends **15**(SUPPL. C): 14-19.
- Mease, P. (2006). "Infliximab (Remicade) in the treatment of psoriatic arthritis." Therapeutics & Clinical Risk Management **2**(4): 389-400.
- Mease, P. (2006). "Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology." Current Rheumatology Reports **8**(5): 348-354.
- Mease, P. and B. S. Goffe (2005). "Diagnosis and treatment of psoriatic arthritis." Journal of the American Academy of Dermatology **52**(1): 1-19.
- Mease, P. J. (2002). "Tumour necrosis factor (TNF) in psoriatic arthritis: Pathophysiology and treatment with TNF inhibitors." Annals of the Rheumatic Diseases **61**(4): 298-304.
- Mease, P. J. (2003). "Current treatment of psoriatic arthritis." Rheumatic Diseases Clinics of North America **29**(3): 495-511.
- Mease, P. J. (2004). "Recent advances in the management of psoriatic arthritis." Current Opinion in Rheumatology **16**(4): 366-370.
- Mease, P. J. (2005). "Adalimumab: An anti-TNF agent for the treatment of psoriatic arthritis." Expert Opinion on Biological Therapy **5**(11): 1491-1504.
- Mease, P. J. and M. A. Menter (2006). "Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective." Journal of the American Academy of Dermatology **54**(4): 685-704.
- Mody, G. M., F. A. Parke, et al. (2003). "Articular manifestations of human immunodeficiency virus infection." Best Practice & Research in Clinical Rheumatology **17**(2): 265-287.
- Mohan, A. K., T. R. Cote, et al. (2004). "Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor." Clinical Infectious Diseases **39**(3): 295-299.
- Moller, B. and P. M. Villiger (2006). "Inhibition of IL-1, IL-6, and TNF-a in immune-mediated inflammatory diseases." Springer Seminars in Immunopathology **27**(4): 391-408.

- Montecucco, C. (2006). "Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies." Drugs **66**(14): 1783-1795.
- Mrowietz, U. and W. H. Boehncke (2006). "Leukocyte adhesion: A suitable for anti-inflammatory drugs." Current Pharmaceutical Design **12**(22): 2825-2831.
- Murray, S. and H. Linardou (2002). "Non-cancer therapeutic antibodies." Expert Opinion on Therapeutic Patents **12**(3): 401-417.
- Myers, R. R., W. M. Campana, et al. (2006). "The role of neuroinflammation in neuropathic pain: Mechanisms and therapeutic targets." Drug Discovery Today **11**(1-2): 8-20.
- Nanda, S. and J. M. Bathon (2004). "Etanercept: A clinical review of current and emerging indications." Expert Opinion on Pharmacotherapy **5**(5): 1175-1186.
- Nash, P. (2006). "Therapies for axial disease in psoriatic arthritis. A systematic review." Journal of Rheumatology **33**(7): 1431-1434.
- Nepom, G. T. (2002). "Therapy of autoimmune diseases: Clinical trials and new biologics." Current Opinion in Immunology **14**(6): 812-815.
- Nestle, F. O. and C. Conrad (2004). "Mechanisms of psoriasis." Drug Discovery Today: Disease Mechanisms **1**(3): 315-319.
- Nickoloff, B. J. and F. O. Nestle (2004). "Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities." Journal of Clinical Investigation **113**(12): 1664-1675.
- Nikolov, N. P. and R. M. Siegel (2005). "All in the family: The TNF-TNFR superfamily in the pathogenesis and treatment of rheumatoid arthritis and other inflammatory diseases." Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents **4**(6): 587-596.
- Numerof, R. P., C. A. Dinarello, et al. (2005). "Cytokines as potential therapeutic targets for inflammatory skin diseases." European Cytokine Network **16**(2): 101-103.
- O'Neill, L. A. J. (2006). "Targeting signal transduction as a strategy to treat inflammatory diseases." Nature Reviews. Drug Discovery **5**(7): 549-563.
- Ornetti, P., H. Chevillotte, et al. (2006). "Anti-tumour necrosis factor- α therapy for rheumatoid and other inflammatory arthropathies: Update on safety in older patients." Drugs & Aging **23**(11): 855-860.
- Palladino, M. A., F. R. Bahjat, et al. (2003). "Anti-TNF- α therapies: The next generation." Nature Reviews. Drug Discovery **2**(9): 736-746.
- Pandya, N. M., N. S. Dhalla, et al. (2006). "Angiogenesis-a new target for future therapy." Vascular Pharmacology **44**(5): 265-274.
- Papachristou, G. and S. Plevy (2004). "Immunospecific Therapy in IBD: Rationale and Practical Application." Practical Gastroenterology **28**(1): 18-30.
- Parchamazad, P., P. Ghazvini, et al. (2005). "Abatacept (CTLA4-Ig, Orencia): An investigational biological compound for the treatment of rheumatoid arthritis." P & T **30**(11): 633-638+643+669.
- Pariser, D. M., J. Bagel, et al. (2007). "National Psoriasis Foundation clinical consensus on disease severity." Archives of Dermatology **143**(2): 239-242.
- Pascher, A. and J. Klupp (2005). "Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: New applications for TNF α inhibitors?" Biodrugs **19**(4): 211-231.
- Paul, A. T., V. M. Gohil, et al. (2006). "Modulating TNF- α signaling with natural products." Drug Discovery Today **11**(15-16): 725-732.
- Paul, S. and A. Keat (2005). "Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor α blockade." Rheumatology **44**(1): 17-23.
- Pavelka, K. (2006). "Adalimumab in the treatment of rheumatoid arthritis." Aging Health **2**(4): 533-545.
- Penn, H. (2006). "Biologic therapies in autoimmune diseases." Clinical Medicine **6**(1): 105-108.
- Peters, S. (2007). "The impact of comorbid atopic disease on asthma: Clinical expression and treatment." Journal of Asthma **44**(3): 149-161.
- Petty, R. E., J. R. Smith, et al. (2003). "Arthritis and uveitis in children: A pediatric rheumatology perspective." American Journal of Ophthalmology **135**(6): 879-884.
- Pien, H. H., A. J. Fischman, et al. (2005). "Using imaging biomarkers to accelerate drug development and clinical trials." Drug Discovery Today **10**(4): 259-266.

- Pipitone, N., L. Boiardi, et al. (2005). "Are steroids alone sufficient for the treatment of giant cell arteritis?" Best Practice & Research in Clinical Rheumatology **19**(2 SPEC. ISS.): 277-292.
- Plosker, G. L. and K. A. Lyseng-Williamson (2007). "Adalimumab: In Crohn's disease." Biodrugs **21**(2): 125-132.
- Prasad, R. and D. Gladman (2004). "Current and investigational treatment of psoriatic arthritis." Expert Opinion on Investigational Drugs **13**(2): 139-150.
- Prous, J. R. (2005). "Annual update 2004/2005 - Treatment of musculoskeletal disorders." Drugs of the Future **30**(2): 181-186.
- Radeke, H. H., R. J. Ludwig, et al. (2005). "Experimental approaches to lymphocyte migration in dermatology in vitro and in vivo." Experimental Dermatology **14**(9): 641-666.
- Reddy, J. G. and E. V. Loftus Jr (2006). "Safety of Infliximab and Other Biologic Agents in the Inflammatory Bowel Diseases." Gastroenterology Clinics of North America **35**(4): 837-855.
- Reed, M. and L. Schachna (2006). "Update on spondyloarthritis." Medicine Today **7**(6): 40-48.
- Ricart, E., G. Bouma, et al. (2002). "The therapeutic spectrum of infliximab and tumor necrosis factor immunomodulation in chronic inflammatory diseases." Drugs of Today **38**(11): 725-744.
- Ritchlin, C. (2006). "Newer therapeutic approaches: Spondyloarthritis and uveitis." Rheumatic Diseases Clinics of North America **32**(1): 75-90.
- Ritchlin, C. T. (2006). "Therapies for psoriatic enthesopathy. A systematic review." Journal of Rheumatology **33**(7): 1435-1438.
- Ritchlin, C. T., E. M. Schwarz, et al. (2004). "RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis." Journal of Musculoskeletal Neuronal Interactions **4**(3): 276-284.
- Roberts, S. and R. C. Butler (2005). "Inflammatory mediators as potential therapeutic targets in the spine." Current Drug Targets - Inflammation & Allergy **4**(2): 257-266.
- Ruderman, E. M. (2002). "Current perspectives in the recognition and management of psoriatic arthritis: Implications for integrated patient care." American Journal of Managed Care **8**(6 SUPPL.): S171-S180.
- Ruderman, E. M. (2003). "Evaluation and management of psoriatic arthritis: The role of biologic therapy." Journal of the American Academy of Dermatology **49**(2 A): S125-S132.
- Ruderman, E. M. and S. Tambar (2004). "Psoriatic arthritis: Prevalence, diagnosis, and review of therapy for the dermatologist." Dermatologic Clinics **22**(4): 477-486.
- Russo, C. and R. Polosa (2005). "TNF- α as a promising therapeutic target in chronic asthma: A lesson from rheumatoid arthritis." Clinical Science **109**(2): 135-142.
- Rychly, J. and B. Nebe (2006). "Therapeutic strategies in autoimmune diseases by interfering with leukocyte endothelium interaction." Current Pharmaceutical Design **12**(29): 3799-3806.
- Saketkoo, L. A. and L. R. Espinoza (2006). "Impact of Biologic Agents on Infectious Diseases." Infectious Disease Clinics of North America **20**(4): 931-961.
- Santamaria-Babi, L. F. (2004). "CLA⁺ T cells in cutaneous diseases." European Journal of Dermatology **14**(1): 13-18.
- Sanzone, A. M. and R. E. Begue (2006). "Hepatitis C and Arthritis: An Update." Infectious Disease Clinics of North America **20**(4): 877-889.
- Satoh, M., S. Iida, et al. (2006). "Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies." Expert Opinion on Biological Therapy **6**(11): 1161-1173.
- Sauder, D. N. (2004). "Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions." Journal of Cutaneous Medicine & Surgery **8**(SUPPL. 3): 3-12.
- Sauder, D. N. and M. Z. Mofid (2005). "Topical immunotherapy: What's new." Dermatologic Clinics **23**(2): 245-258.
- Scalapino, K. J. and J. C. Davis Jr (2003). "The treatment of ankylosing spondylitis." Clinical & Experimental Medicine **2**(4): 159-165.
- Scheinfeld, N. (2005). "Adalimumab: A review of side effects." Expert Opinion on Drug Safety **4**(4): 637-641.
- Scheinfeld, N. (2006). "Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists." Journal of Dermatological Treatment **17**(4): 229-234.

- Schett, G. and J. S. Smolen (2005). "New insights in the mechanism of bone loss in arthritis." Current Pharmaceutical Design **11**(23): 3039-3049.
- Schmidt, W. A. (2006). "Current diagnosis and treatment of temporal arteritis." Current Treatment Options in Cardiovascular Medicine **8**(2): 145-151.
- Schmidt, W. A. (2007). "Technology insight: The role of color and power Doppler ultrasonography in rheumatology." Nature Clinical Practice Rheumatology **3**(1): 35-42.
- Schon, M. P., T. M. Zollner, et al. (2003). "The Molecular Basis of Lymphocyte Recruitment to the Skin: Clues for Pathogenesis and Selective Therapies of Inflammatory Disorders." Journal of Investigative Dermatology **121**(5): 951-962.
- Schroder, O. and J. Stein (2003). "Low dose methotrexate in inflammatory bowel disease: Current status and future directions." American Journal of Gastroenterology **98**(3): 530-537.
- Schwartzman, S., R. Fleischmann, et al. (2004). "Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?" Arthritis Research & Therapy **6**(SUPPL. 2): S3-S11.
- Shanahan, J. C., L. W. Moreland, et al. (2003). "Upcoming biologic agents for the treatment of rheumatic diseases." Current Opinion in Rheumatology **15**(3): 226-236.
- Siddiqui, M. A. A. and L. J. Scott (2005). "Infliximab: A review of its use in Crohn's disease and rheumatoid arthritis." Drugs **65**(15): 2179-2208.
- Sieper, J. and J. Braun (2002). "Anti-TNF agents for the treatment of spondyloarthropathies." Expert Opinion on Emerging Drugs **7**(2): 235-246.
- Simmons, D. L. (2005). "Anti-adhesion therapies." Current Opinion in Pharmacology **5**(4 SPEC. ISS.): 398-404.
- Sitaraman, S. V., M. Hoteit, et al. (2003). "Semapimod cytokine." Current Opinion in Investigational Drugs **4**(11): 1363-1368.
- Skurkovich, B. and S. Skurkovich (2003). "Anti-interferon-gamma antibodies in the treatment of autoimmune diseases." Current Opinion in Molecular Therapeutics **5**(1): 52-57.
- Staunton, D. E., M. L. Lupher, et al. (2006). "Targeting Integrin Structure and Function in Disease." Advances in Immunology **91**(pp 111-157).
- Stebbins, W. G. and M. G. Lebwohl (2004). "Biologics in combination with nonbiologics: Efficacy and safety." Dermatologic Therapy **17**(5): 432-440.
- Stefanidakis, M. and E. Koivunen (2006). "Cell-surface association between matrix metalloproteinases and integrins: Role of the complexes in leukocyte migration and cancer progression." Blood **108**(5): 1441-1450.
- Stokes, D. G. and J. M. Kremer (2003). "Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis." Seminars in Arthritis & Rheumatism **33**(1): 1-18.
- Stowell, C. P. (2006). "Therapy with immunoglobulin: applications for monoclonal antibodies." Journal of Infusion Nursing **29**(3 SUPPL.): S29-S44.
- Strand, V., R. Kimberly, et al. (2007). "Biologic therapies in rheumatology: Lessons learned, future directions." Nature Reviews. Drug Discovery **6**(1): 75-92.
- Szekanecz, Z. and A. E. Koch (2005). "Endothelial cells in inflammation and angiogenesis." Current Drug Targets - Inflammation & Allergy **4**(3): 319-323.
- Takeuchi, T., K. Amano, et al. (2005). "Anti-TNF biological agents in rheumatoid arthritis and other inflammatory diseases." Allergology International **54**(2): 191-202.
- Tandon, V. R., A. Mahajan, et al. (2006). "Biologics and challenges ahead for the physician." Journal Indian Academy of Clinical Medicine **7**(4): 334-343.
- Tauscher, A. E., A. B. Fleischer Jr, et al. (2002). "Psoriasis and pregnancy." Journal of Cutaneous Medicine & Surgery **6**(6): 561-570.
- Tavarella Veloso, F. (2004). "Review article: Skin complications associated with inflammatory bowel disease." Alimentary Pharmacology & Therapeutics, Supplement **20**(4): 50-53.
- Taylor, P. C., R. O. Williams, et al. (2004). "Tumour necrosis factor as a therapeutic target for immune-mediated inflammatory diseases." Current Opinion in Biotechnology **15**(6): 557-563.

- Taylor, W. J. (2004). "Assessment of outcome in psoriatic arthritis." Current Opinion in Rheumatology 16(4): 350-356.
- Teillaud, J. L. (2005). "Engineering of monoclonal antibodies and antibody-based fusion proteins: Successes and challenges." Expert Opinion on Biological Therapy 5(SUPPL. 1): S15-S27.
- Teng, G. G., A. M. Turkiewicz, et al. (2005). "Abatacept: A costimulatory inhibitor for treatment of rheumatoid arthritis." Expert Opinion on Biological Therapy 5(9): 1245-1254.
- Theoharides, T. C. (2007). "Treatment approaches for painful bladder syndrome/interstitial cystitis." Drugs 67(2): 215-235.
- Tilg, H. and A. Kaser (2004). "Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders." Expert Opinion on Biological Therapy 4(4): 469-481.
- Tilg, H., A. Kaser, et al. (2006). "How to modulate inflammatory cytokines in liver diseases." Liver International 26(9): 1029-1039.
- Todd, D. J., K. H. Costenbader, et al. (2007). "Abatacept in the treatment of rheumatoid arthritis." International Journal of Clinical Practice 61(3): 494-500.
- Travassos, W. J. and A. S. Cheifetz (2005). "Infliximab: Use in inflammatory bowel disease." Current Treatment Options in Gastroenterology 8(3): 187-196.
- Tsimberidou, A. M. and F. J. Giles (2002). "TNF- α targeted therapeutic approaches in patients with hematologic malignancies." Expert Review of Anticancer Therapy 2(3): 277-286.
- Ulbrich, H., E. E. Eriksson, et al. (2003). "Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease." Trends in Pharmacological Sciences 24(12): 640-647.
- Vally, M., S. Seenu, et al. (2006). "Emerging peptide therapeutics for inflammatory diseases." Current Pharmaceutical Biotechnology 7(4): 241-246.
- Van Assche, G. (2007). "Emerging drugs to treat Crohn's disease." Expert Opinion on Emerging Drugs 12(1): 49-59.
- Van Assche, G., S. Vermeire, et al. (2006). "Safety issues with biological therapies for inflammatory bowel disease." Current Opinion in Gastroenterology 22(4): 370-376.
- Van De Kerkhof, P. C. M. (2006). "Update on retinoid therapy of psoriasis in: An update on the use of retinoids in dermatology." Dermatologic Therapy 19(5): 252-263.
- van Roon, J. A. G., J. W. J. Bijlsma, et al. (2006). "Diversity of regulatory T cells to control arthritis." Best Practice & Research in Clinical Rheumatology 20(5): 897-913.
- Van Walle, I., Y. Gansemans, et al. (2007). "Immunogenicity screening in protein drug development." Expert Opinion on Biological Therapy 7(3): 405-418.
- Vanderslice, P. and D. G. Woodside (2006). "Integrin antagonists as therapeutics for inflammatory diseases." Expert Opinion on Investigational Drugs 15(10): 1235-1255.
- Veale, D. J. and U. Fearon (2006). "Inhibition of angiogenic pathways in rheumatoid arthritis: potential for therapeutic targeting." Best Practice & Research in Clinical Rheumatology 20(5): 941-947.
- Verbruggen, G., R. Wittoek, et al. (2007). "Osteochondral repair in synovial joints." Current Opinion in Rheumatology 19(3): 265-271.
- Vermeire, S., G. Van Assche, et al. (2007). "Review article: Altering the natural history of Crohn's disease - Evidence for and against current therapies." Alimentary Pharmacology & Therapeutics 25(1): 3-12.
- Vital, E. M. and P. Emery (2006). "Abatacept in the treatment of rheumatoid arthritis." Therapeutics & Clinical Risk Management 2(4): 365-375.
- Vizcarra, C. (2003). "New Perspectives and Emerging Therapies for Immune-mediated Inflammatory Disorders." Journal of Infusion Nursing 26(5): 319-325.
- Vizcarra, C. and D. Belcher (2006). "Management of the patient receiving parenteral biologic therapy." Journal of Infusion Nursing 29(2): 63-71.
- Walsh, G. (2005). "Biopharmaceuticals: Recent approvals and likely directions." Trends in Biotechnology 23(11): 553-558.
- Walsh, N. C., T. N. Crotti, et al. (2005). "Rheumatic diseases: The effects of inflammation on bone." Immunological Reviews 208(pp 228-251).

- Weber, R. W. (2004). "Adverse reactions to biological modifiers." Current Opinion in Allergy & Clinical Immunology 4(4): 277-283.
- Wei, J.-C., J. L. Lan, et al. (2006). "Experience of antitumor necrosis factor- α therapies in Taiwan." APLAR Journal of Rheumatology 9(2): 161-164.
- Wendling, D. and E. Toussirot (2004). "Anti-TNF- α therapy in ankylosing spondylitis." Expert Opinion on Pharmacotherapy 5(7): 1497-1507.
- Weyand, C. M. and J. J. Goronzy (2006). "T-cell-targeted therapies in rheumatoid arthritis." Nature Clinical Practice Rheumatology 2(4): 201-210.
- Wilson, J. F. (2004). "Angiogenesis therapy moves beyond cancer." Annals of Internal Medicine 141(2): 165-168.
- Wolf, R., H. Matz, et al. (2002). "Anti-TNF therapies - The hope of tomorrow." Clinics in Dermatology 20(5): 522-530.
- Wolff, K. and A. Stuetz (2004). "Pimecrolimus for the treatment of inflammatory skin disease." Expert Opinion on Pharmacotherapy 5(3): 643-655.
- Wolfram, L. A. (2006). "Treating autoimmune diseases through restoration of antigen-specific immune tolerance." Archivum Immunologiae et Therapiae Experimentalis 54(1): 1-13.
- Woolacott, N. F., Z. C. S. Khadjesari, et al. (2006). "Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review." Clinical & Experimental Rheumatology 24(5): 587-93.
- Woolacott, N., Y. B. Vergel, et al. (2006). "Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review and economic evaluation." Health Technology Assessment (Winchester, England) 10(46)
- Woolacott, N., Y. Bravo Vergel, et al. (2006). "Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation." Health Technology Assessment 10(31): iii-iv, xiii-xvi, 1-239.
- Yonekawa, K. and J. M. Harlan (2005). "Targeting leukocyte integrins in human diseases." Journal of Leukocyte Biology 77(2): 129-140.
- Zitter, M. (2004). "Defining the great debate." American Journal of Managed Care 10(SUPPL. 8): S231-S239.
- Zochling, J. and J. Braun (2005). "Management and treatment of ankylosing spondylitis." Current Opinion in Rheumatology 17(4): 418-425.
- Zochling, J., J. Brandt, et al. (2005). "The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis." Rheumatology 44(12): 1483-1491.

Psoriasis therapy not involving licensed infliximab, etanercept or efalizumab (n=64)

- Ameen, M. (2003). "Genetic basis of psoriasis vulgaris and its pharmacogenetic potential." Pharmacogenomics 4(3): 297-308.
- Anker, S. D. and A. J. S. Coats (2002). "How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH." International Journal of Cardiology 86(2-3): 123-130.
- Anonymous (2003). "(Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents." Expert Opinion on Therapeutic Patents 13(3): 381-385.
- Asadullah, K., H. D. Volk, et al. (2002). "Experimental therapies for psoriasis." Archivum Immunologiae et Therapiae Experimentalis 50(6): 411-420.
- Bachelez, H. (2005). "Immunopathogenesis of psoriasis: Recent insights on the role of adaptive and innate immunity." Journal of Autoimmunity 25(SUPPL.): 69-73.
- Baker, D. E. (2004). "Adalimumab: Human recombinant immunoglobulin G1 anti-tumor necrosis factor monoclonal antibody." Reviews in Gastroenterological Disorders 4(4): 196-210.
- Basu, S. K., C. P. Govardhan, et al. (2004). "Protein crystals for the delivery of biopharmaceuticals." Expert Opinion on Biological Therapy 4(3): 301-317.
- Berth-Jones, J. (2005). "The use of ciclosporin in psoriasis." Journal of Dermatological Treatment 16(5-6): 258-277.
- Bhosle, M. J., A. Kulkarni, et al. "Quality of life in patients with psoriasis." Journal.

- Bock, D., S. Philipp, et al. (2006). "Therapeutic potential of selectin antagonists in psoriasis." Expert Opinion on Investigational Drugs **15**(8): 963-979.
- Bombardieri, M., I. B. McInnes, et al. (2007). "Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions." Expert Opinion on Biological Therapy **7**(1): 31-40.
- Boonen, A. and S. M. Van Der Linden (2006). "The burden of ankylosing spondylitis." Journal of Rheumatology **33**(SUPPL. 78): 4-11.
- Bos, J. D., M. A. De Rie, et al. (2005). "Psoriasis: Dysregulation of innate immunity." British Journal of Dermatology **152**(6): 1098-1107.
- Brown, L. R. (2005). "Commercial challenges of protein drug delivery." Expert Opinion on Drug Delivery **2**(1): 29-42.
- Chamian, F. and J. G. Krueger (2004). "Psoriasis vulgaris: An interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis." Current Opinion in Rheumatology **16**(4): 331-337.
- Gaspari, A. A. (2006). "Innate and adaptive immunity and the pathophysiology of psoriasis." Journal of the American Academy of Dermatology **54**(3 SUPPL. 2): S67-S80.
- Griffiths, C. E. M. (2004). "Psoriasis: Future research needs and goals for the twenty-first century." Dermatologic Clinics **22**(4): 493-499.
- Guenther, L. C. and J. P. Ortonne (2002). "Pathophysiology of psoriasis: Science behind therapy." Journal of Cutaneous Medicine & Surgery **6**(3 SUPPL.): 2-7.
- Kaltwasser, J. P. and F. Behrens (2005). "Leflunomide: Long-term clinical experience and new uses." Expert Opinion on Pharmacotherapy **6**(5): 787-801.
- Katugampola, R. P., V. J. Lewis, et al. (2007). "The dermatology life quality index: Assessing the efficacy of biological therapies for psoriasis." British Journal of Dermatology **156**(5): 945-950.
- Kennewell, P. (2003). "Technology evaluation: ISIS-104838, OraSense." Current Opinion in Molecular Therapeutics **5**(1): 76-80.
- Kerns, M., J. E. Graves, et al. (2006). "Off-Label Uses of Biologic Agents in Dermatology: A 2006 Update." Seminars in Cutaneous Medicine & Surgery **25**(4): 226-240.
- Khobzaoui, M., H. J. Gutke, et al. (2005). "CC-10004 Celgene." Current Opinion in Investigational Drugs **6**(5): 518-525.
- Korman, N. J. and D. K. Moul (2005). "Alefacept for the treatment of psoriasis: A review of the current literature and practical suggestions for everyday clinical use." Seminars in Cutaneous Medicine & Surgery **24**(1): 10-18.
- Krakauer, T. (2004). "Molecular therapeutic targets in inflammation: Cyclooxygenase and NF-kappaB." Current Drug Targets - Inflammation & Allergy **3**(3): 317-324.
- Krueger, G. G. (2004). "Current concepts and review of alefacept in the treatment of psoriasis." Dermatologic Clinics **22**(4): 407-426.
- Krueger, J. G. (2002). "The immunologic basis for the treatment of psoriasis with new biologic agents." Journal of the American Academy of Dermatology **46**(1): 1-23.
- Kupper, T. S. (2003). "Immunologic Targets in Psoriasis." New England Journal of Medicine **349**(21): 1987-1990.
- Le, G. T. and G. Abbenante (2005). "Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs." Current Medicinal Chemistry **12**(25): 2963-2977.
- Lee, C. S. and J. Koo (2005). "A review of acitretin, a systemic retinoid for the treatment of psoriasis." Expert Opinion on Pharmacotherapy **6**(10): 1725-1734.
- Malhotra, S., D. Bansal, et al. (2005). "Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis." Expert Opinion on Pharmacotherapy **6**(9): 1455-1461.
- Manriquez, J. J., M. F. Villouta, et al. (2007). "Evidence-based dermatology: Number needed to treat and its relation to other risk measures." Journal of the American Academy of Dermatology **56**(4): 664-671.
- Marsland, A. M. and C. E. M. Griffiths (2004). "Therapeutic potential of macrolide immunosuppressants in dermatology." Expert Opinion on Investigational Drugs **13**(2): 125-137.

- Maryles, S., M. Rozenblit, et al. (2003). "Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis." Journal of Dermatological Treatment **14**(SUPPL. 2): 7-16.
- Mashhood, A. A. and A. Imran (2005). "Pathogenesis of psoriasis." Journal of Pakistan Association of Dermatologists **15**(1): 42-54.
- Mayer, L. and Y. Young (2006). "Infusion reactions and their management." Gastroenterology Clinics of North America **35**(4): 857-866.
- Mehlis, S. and K. B. Gordon (2004). "From laboratory to clinic: Rationale for biologic therapy." Dermatologic Clinics **22**(4): 371-377.
- Mendonca, C. O. and A. D. Burden (2003). "Current concepts in psoriasis and its treatment." Pharmacology & Therapeutics **99**(2): 133-147.
- Morison, W. L. (2004). "Psoralen ultraviolet A therapy in 2004." Photodermatology, Photoimmunology & Photomedicine **20**(6): 315-320.
- Nickoloff, B. J. and S. R. Stevens (2006). "What have we learned in dermatology from the biologic therapies?" Journal of the American Academy of Dermatology **54**(3 SUPPL. 2): S143-S151.
- Nikas, S. N. and A. A. Drosos (2003). "Onercept Serono." Current Opinion in Investigational Drugs **4**(11): 1369-1376.
- Numerof, R. P. and K. Asadullah (2006). "Cytokine and anti-cytokine therapies for psoriasis and atopic dermatitis." Biodrugs **20**(2): 93-103.
- Ormerod, A. D. (2001). "What is new in therapy?" British Journal of Dermatology **145**(5): 691-695.
- Ormerod, A. D. (2003). "Alefacept Biogen." Current Opinion in Investigational Drugs **4**(5): 608-613.
- Pham, D. Q., V. Bandy, et al. (2002). "Alefacept: A T-cell-specific immunosuppressant to treat moderate to severe plaque psoriasis." Formulary **37**(7): 346-353.
- Philipp, S., K. Wolk, et al. (2006). "The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder." Expert Opinion on Therapeutic Targets **10**(6): 817-831.
- Qureshi, A. A., M. E. Husni, et al. (2005). "Psoriatic arthritis and psoriasis: Need for a multidisciplinary approach." Seminars in Cutaneous Medicine & Surgery **24**(1): 46-51.
- Rott, S. and U. Mrowietz (2005). "Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies." British Medical Journal **330**(7493): 716-720.
- Schon, M. P. and R. J. Ludwig (2005). "Lymphocyte trafficking to inflamed skin - Molecular mechanisms and implications for therapeutic target molecules." Expert Opinion on Therapeutic Targets **9**(2): 225-243.
- Schottelius, A. J. G., L. L. Moldawer, et al. (2004). "Biology of tumor necrosis factor- α - Implications for psoriasis." Experimental Dermatology **13**(4): 193-222.
- Shear, N. H. (2006). "Fulfilling an unmet need in psoriasis: Do biologicals hold the key to improved tolerability?" Drug Safety **29**(1): 49-66.
- Singri, P., D. P. West, et al. (2002). "Biologic therapy for psoriasis: The new therapeutic frontier." Archives of Dermatology **138**(5): 657-663.
- Sticherling, M. (2005). "Mechanisms of psoriasis." Drug Discovery Today: Disease Mechanisms **2**(2): 275-281.
- Thappa, D. M. and C. Laxmisha (2004). "Immunomodulators in the treatment of psoriasis." Indian Journal of Dermatology, Venereology & Leprology **70**(1): 1-9.
- Travis, L. and J. M. Weinberg (2002). "Medical background: Psoriasis." Drugs of Today **38**(12): 847-865.
- Trefzer, U., M. Hofmann, et al. (2003). "Cytokine and anticytokine therapy in dermatology." Expert Opinion on Biological Therapy **3**(5): 733-743.
- Victor, F. C., A. B. Gottlieb, et al. (2003). "Changing paradigms in dermatology: Tumor necrosis factor α (TNF- α) blockade in psoriasis and psoriatic arthritis." Clinics in Dermatology **21**(5): 392-397.
- Villadsen, L. S., L. Skov, et al. (2003). "Biological response modifiers and their potential use in the treatment of inflammatory skin diseases." Experimental Dermatology **12**(1): 1-10.

- Walsh, S. R. A. and N. H. Shear (2004). "Psoriasis and the new biologic agents: Interrupting a T-AP dance." CMAJ: Canadian Medical Association Journal **170**(13): 1933-1941.
- Wilsmann-Theis, D., S. Martin, et al. (2006). "Biologics dramatic advances in the treatment of psoriasis." Current Pharmaceutical Design **12**(8): 989-999.
- Winterfield, L. and A. Menter (2004). "Psoriasis and its treatment with infliximab-mediated tumor necrosis factor a blockade." Dermatologic Clinics **22**(4): 437-447.
- Yamauchi, P. S., D. Rizk, et al. (2004). "Retinoid therapy for psoriasis." Dermatologic Clinics **22**(4): 467-476.
- Zanolli, M. (2004). "Phototherapy arsenal in the treatment of psoriasis." Dermatologic Clinics **22**(4): 397-406.
- Zollner, T. M., K. Asadullah, et al. (2007). "Targeting leukocyte trafficking to inflamed skin - Still an attractive therapeutic approach?" Experimental Dermatology **16**(1): 1-12.

Not RCT efficacy evidence (n=84)

- Adorini, L. (2003). "Cytokine-based immunointervention in the treatment of autoimmune diseases." Clinical & Experimental Immunology **132**(2): 185-192.
- Agarwal, R., N. Vij, et al. (2002). "Biotherapy: A novel approach in the treatment of psoriasis." Drugs of the Future **27**(11): 1071-1077.
- Andreaskos, E. (2003). "Targeting cytokines in autoimmunity: New approaches, new promise." Expert Opinion on Biological Therapy **3**(3): 435-447.
- Andreaskos, E. (2005). "Monoclonal antibodies for immunological disorders: A review of recent patents." Expert Opinion on Therapeutic Patents **15**(9): 1105-1114.
- Andreaskos, E., P. C. Taylor, et al. (2002). "Monoclonal antibodies in immune and inflammatory diseases." Current Opinion in Biotechnology **13**(6): 615-620.
- Anonymous (2003). "Annual update 2003: Dermatologic drugs." Drugs of the Future **28**(2): 175-209.
- Anonymous (2006). "As there are no simple rules for dermatological drug dosing in the elderly, titrate to suit individual response." Drugs & Therapy Perspectives **22**(10): 23-26.
- Asadullah, K., H. D. Volk, et al. (2002). "Novel immunotherapies for psoriasis." Trends in Immunology **23**(1): 47-53.
- Barry, J. and B. Kirby (2004). "Novel biologic therapies for psoriasis." Expert Opinion on Biological Therapy **4**(6): 975-987.
- Bayes, M., X. Rabasseda, et al. (2004). "Gateways to Clinical Trials." Methods & Findings in Experimental & Clinical Pharmacology **26**(9): 723-753.
- Bayes, M., X. Rabasseda, et al. (2005). "Gateways to Clinical Trials: January/February 2005." Methods & Findings in Experimental & Clinical Pharmacology **27**(1): 49-77.
- Bayes, M., X. Rabasseda, et al. (2006). "Gateways to clinical trials." Methods & Findings in Experimental & Clinical Pharmacology **28**(5): 323-343.
- Bayliffe, A. I., R. A. Brigandi, et al. (2004). "Emerging therapeutic targets in psoriasis." Current Opinion in Pharmacology **4**(3): 306-310.
- Braddock, M., A. Quinn, et al. (2004). "Therapeutic potential of targeting IL-1 and IL-18 in inflammation." Expert Opinion on Biological Therapy **4**(6): 847-860.
- Brandt, J. and J. Braun (2006). "Anti-TNF-a agents in the treatment of psoriatic arthritis." Expert Opinion on Biological Therapy **6**(2): 99-107.
- Callen, J. P. (2007). "Complications and Adverse Reactions in the Use of Newer Biologic Agents." Seminars in Cutaneous Medicine & Surgery **26**(1): 6-14.
- Cather, J. and A. Menter (2002). "Novel therapies for psoriasis." American Journal of Clinical Dermatology **3**(3): 159-173.
- Cayce, K. A., C. L. Carroll, et al. (2004). "A red, scaly rash: How to recognize and treat psoriasis." Journal of Clinical Outcomes Management **11**(7): 463-474.
- Craze, M. and M. Young (2003). "Integrating biologic therapies into a dermatology practice: Practical and economic considerations." Journal of the American Academy of Dermatology **49**(2 A): S139-S142.
- Dogra, A. and S. Sachdeva (2006). "Biologic therapy in psoriasis." Indian Journal of Dermatology, Venereology & Leprology **72**(4): 256-265.

- Elston, D. M. (2004). "Biologic agents for psoriasis: A primer." Cosmetic Dermatology 17(10): 649-652.
- Fairhurst, D. A., D. M. Ashcroft, et al. (2005). "Optimal management of severe plaque form of psoriasis." American Journal of Clinical Dermatology 6(5): 283-294.
- Feldman, S. R. and D. J. Pearce (2004). "Management and costs of severe psoriasis: The role of new biologics." Expert Review of Pharmacoeconomics & Outcomes Research 4(5): 573-579.
- Feldman, S. R., R. Garton, et al. (2003). "Strategy to manage the treatment of severe psoriasis: Considerations of efficacy, safety and cost." Expert Opinion on Pharmacotherapy 4(9): 1525-1533.
- Feldmann, M., F. M. Brennan, et al. (2005). "Anti-TNF therapy: Where have we got to in 2005?" Journal of Autoimmunity 25(SUPPL.): 26-28.
- Finlay, A. Y. and J. P. Ortonne (2004). "Patient satisfaction with psoriasis therapies: An update and introduction to biologic therapy." Journal of Cutaneous Medicine & Surgery 8(5): 310-320.
- Fleischmann, R. (2006). "Safety and efficacy of etanercept in the elderly." Aging Health 2(2): 189-197.
- Fleischmann, R., R. Stern, et al. (2004). "Etanercept - Review of efficacy and safety after five years of clinical use." Therapy 1(1): 11-23.
- Ghaffar, S. A., S. E. Clements, et al. (2005). "Modern management of psoriasis." Clinical Medicine 5(6): 564-568.
- Girolomoni, G., S. Pastore, et al. (2002). "Targeting tumor necrosis factor- α as a potential therapy in inflammatory skin diseases." Current Opinion in Investigational Drugs 3(11): 1590-1595.
- Gisoni, P., E. Gubinelli, et al. (2004). "Targeting tumor necrosis factor- α in the therapy of psoriasis." Current Drug Targets - Inflammation & Allergy 3(2): 175-183.
- Gniadecki, R., C. Zachariae, et al. (2002). "Trends and developments in the pharmacological treatment of psoriasis." Acta Dermato-Venereologica 82(6): 401-410.
- Gordon, K. B. and E. M. Ruderman (2006). "The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach." Journal of the American Academy of Dermatology 54(3 SUPPL. 2): S85-S91.
- Gottlieb, A. B. (2001). "Psoriasis: Immunopathology and immunomodulation." Dermatologic Clinics 19(4): 649-657.
- Gottlieb, A. B. (2005). "Psoriasis: Emerging therapeutic strategies." Nature Reviews. Drug Discovery 4(1): 19-34.
- Gottlieb, A. B. (2005). "Therapeutic options in the treatment of psoriasis and atopic dermatitis." Journal of the American Academy of Dermatology 53(1 SUPPL.): S3-S16.
- Griffiths, C. E. M. (2004). "T-cell-targeted biologicals for psoriasis." Current Drug Targets - Inflammation & Allergy 3(2): 157-161.
- Griffiths, C. E. M., L. Iaccarino, et al. (2006). "Psoriasis and psoriatic arthritis: Immunological aspects and therapeutic guidelines." Clinical & Experimental Rheumatology 24(SUPPL. 40): S72-S78.
- Gupta, A. K. and A. R. Skinner (2004). "A review of the use of infliximab to manage cutaneous dermatoses." Journal of Cutaneous Medicine & Surgery 8(2): 77-89.
- Hankin, C. S., S. R. Feldman, et al. (2005). "A cost comparison of treatments of moderate to severe psoriasis." Drug Benefit Trends 17(5): 200-214.
- Jacobi, A., V. Mahler, et al. (2006). "Treatment of inflammatory dermatoses by tumour necrosis factor antagonists." Journal of the European Academy of Dermatology & Venereology 20(10): 1171-1187.
- Kanitakis, J., A. C. Butnaru, et al. (2003). "Novel biological immunotherapies for psoriasis." Expert Opinion on Investigational Drugs 12(7): 1111-1121.
- Kazlow Stern, D., J. M. Tripp, et al. (2005). "The use of systemic immune moderators in dermatology: An update." Dermatologic Clinics 23(2): 259-300.
- Kirby, B. and C. E. M. Griffiths (2002). "Novel immune-based therapies for psoriasis." British Journal of Dermatology 146(4): 546-551.
- Kormeili, T., N. J. Lowe, et al. (2004). "Psoriasis: Immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences." British Journal of Dermatology 151(1): 3-15.
- Kourbeti, I. S. and D. T. Boumpas (2005). "Biological therapies of autoimmune diseases." Current Drug Targets - Inflammation & Allergy 4(1): 41-46.

- Lamberg, L. (2003). "A Host of Novel Agents for Treating Psoriasis, Psoriatic Arthritis Stir Interest." Jama **289**(21): 2779-2783.
- Langley, R. G., V. Ho, et al. (2005). "Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: Individualized patient approaches." Journal of Cutaneous Medicine & Surgery **9**(SUPPL. 1): 18-25.
- Lebwohl, M. G. (2005). "Use of etanercept in the dermatology setting: A review." American Journal of Clinical Dermatology **6**(1): 49-59.
- Lebwohl, M., A. Menter, et al. (2003). "Case studies in severe psoriasis: A clinical strategy." Journal of Dermatological Treatment **14**(SUPPL. 2): 26-46.
- Lisby, S. (2004). "Use of biological response modifiers in dermatology - Preliminary recommendations for the treatment of psoriasis." Forum for Nordic Dermato-Venerology **9**(3): 64-69+92.
- Lowes, M. A., A. M. Bowcock, et al. (2007). "Pathogenesis and therapy of psoriasis." Nature **445**(7130): 866-873.
- Lynde, C. (2005). "Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis." Journal of Cutaneous Medicine & Surgery **9**(SUPPL. 1): 1-3.
- Magliocco, M. A. (2005). "Emerging drugs for moderate-to-severe psoriasis." Expert Opinion on Emerging Drugs **10**(1): 35-52.
- Menter, A. and T. Baker (2005). "Cost-efficacy analysis of biological treatments in psoriasis: An 18-month assessment." Journal of Medical Economics **8**(139-146): 139-146.
- Mikhail, M. and N. S. Scheinfeld (2004). "Therapy treatment options for psoriasis: Topical and systemic." Therapy **1**(2): 319-330.
- Miller, D. W. and S. R. Feldman (2006). "Cost-effectiveness of moderate-to-severe psoriasis treatment." Expert Opinion on Pharmacotherapy **7**(2): 157-167.
- Mrowietz, U. (2001). "Advances in systemic therapy for psoriasis." Clinical & Experimental Dermatology **26**(4): 362-367.
- Papp, K. A. (2004). "Advancing psoriasis management with a novel, targeted T-cell modulator." Drugs of Today **40**(11): 889-899.
- Papp, K. A. (2005). "Potential future therapies for psoriasis." Seminars in Cutaneous Medicine & Surgery **24**(1): 58-63.
- Papp, K. A., V. Ho, et al. (2005). "Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis." Journal of Cutaneous Medicine & Surgery **9**(SUPPL. 1): 26-32.
- Pearce, D. J., K. B. Higgins, et al. (2006). "Adverse events from systemic therapies for psoriasis are common in clinical practice." Journal of Dermatological Treatment **17**(5): 288-293.
- Poulin, Y., K. A. Papp, et al. (2005). "A favourable benefit/risk ratio with efalizumab: A review of the clinical evidence." Journal of Cutaneous Medicine & Surgery **9**(SUPPL. 1): 10-17.
- Poulin, Y., K. A. Papp, et al. (2006). "A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence." Journal of Cutaneous Medicine & Surgery **9 Suppl 1**: 10-7.
- Rajpara, S. M., A. D. Ormerod, et al. (2006). "Biological treatments for psoriasis." Therapy **3**(3): 425-436.
- Riddle, C., M. Young, et al. (2004). "Practical considerations in future psoriasis therapies." Dermatologic Clinics **22**(4): 487-492.
- Saini, R., W. D. Tutrone, et al. (2004). "Novel therapies for psoriasis: Infliximab, etanercept, efalizumab, and alefacept." Cosmetic Dermatology **17**(9): 563-566+569.
- Sanchez Carazo, J. L., L. M. Santos, et al. (2006). "Safety of etanercept in psoriasis: A critical review." Drug Safety **29**(8): 675-685.
- Sauder, D. N. and A. J. Mamelak (2005). "Understanding the new clinical landscape for psoriasis: A comparative review of biologics." Journal of Cutaneous Medicine & Surgery **8**(4): 205-212.
- Scheinfeld, N. S. (2005). "Psoriasis: The 'nuts and bolts' of management." Consultant **45**(7): 798-807.
- Schleyer, V., M. Landthaler, et al. (2005). "Novel pharmacological approaches in the treatment of psoriasis." Journal of the European Academy of Dermatology & Venereology **19**(1): 1-20.
- Smith, C. H. and J. Barker (2006). "Psoriasis and its management." British Medical Journal **333**(7564): 380-384.

- Sobell, J. M. (2005). "Overview of biologic agents in medicine and dermatology." Seminars in Cutaneous Medicine & Surgery **24**(1): 2-9.
- Stein, K. R., D. J. Pearce, et al. (2005). "The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care." Seminars in Cutaneous Medicine & Surgery **24**(1): 52-57.
- Stockwin, L. H. and S. Holmes (2003). "Antibodies as therapeutic agents: Vive la renaissance!" Expert Opinion on Biological Therapy **3**(7): 1133-1152.
- Tam, J. W., G. J. Lee, et al. (2004). "Efalizumab: A new biologic therapy for the control of chronic plaque psoriasis." Formulary **39**(1): 20-39.
- Thielen, A. M., S. Kuenzli, et al. (2005). "Cutaneous adverse events of biological therapy for psoriasis: Review of the literature." Dermatology **211**(3): 209-217.
- Thomas, V. D., F. C. Yang, et al. (2005). "Biologics in psoriasis: A quick reference guide." Journal of the American Academy of Dermatology **53**(2): 346-351.
- Tobin, A. M. and B. Kirby (2005). "TNFa inhibitors in the treatment of psoriasis and psoriatic arthritis." Biodrugs **19**(1): 47-57.
- Tsourounis, C. and C. Cheng (2005). "Biologic therapies for the treatment of chronic plaque psoriasis." Formulary **40**(6): 184-199.
- Tzu, J., A. J. Mamelak, et al. (2006). "Current advancements in the treatment of psoriasis: Immunobiologic agents." Clinical & Applied Immunology Reviews **6**(2): 99-130.
- Weinberg, J. M., R. Buchholz, et al. (2005). "Evidence-based review of biologic therapy for psoriasis: Infliximab, etanercept, adalimumab, efalizumab, and alefacept." Advanced Studies in Medicine **5**(4): 195-206.
- Weinberg, W. C., M. R. Frazier-Jessen, et al. (2005). "Development and regulation of monoclonal antibody products: Challenges and opportunities." Cancer & Metastasis Reviews **24**(4): 569-584.
- Zeichner, J. A. and M. Lebwohl (2007). "Potential Complications Associated with the Use of Biologic Agents for Psoriasis." Dermatologic Clinics **25**(2): 207-213.

Included Journal Articles

Infliximab (n=4)

- Chaudhari, U., P. Romano, et al. (2001). "Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial." Lancet **357**(9271): 1842-7.
- Gottlieb, A. B., R. Evans, et al. (2004). "Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial." Journal of the American Academy of Dermatology **51**(4): 534-42.
- Reich, K., F. O. Nestle, et al. (2005). "Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial." Lancet **366**(9494): 1367-1374.
- Menter, A., S. R. Feldman, et al. (2007). "A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis." Journal of the American Academy of Dermatology **56**(1): 31.e1-15.

Etanercept (n=4)

- Gottlieb, A. B., R. T. Matheson, et al. (2003). "A Randomized Trial of Etanercept as Monotherapy for Psoriasis." Archives of Dermatology **139**(12): 1627-1632.
- Leonardi, C. L., J. L. Powers, et al. (2003). "Etanercept as Monotherapy in Patients with Psoriasis." New England Journal of Medicine **349**(21): 2014-2022.
- Papp, K. A., S. Tying, et al. (2005). "A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction." British Journal of Dermatology **152**(6): 1304-1312.
- Tying, S., A. Gottlieb, et al. (2006). "Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial." Lancet **367**(9504): 29-35.

Efalizumab (n=4)

Dubertret, L., W. Sterry, et al. (2006). "Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial." British Journal of Dermatology **155**(1): 170-181.

NOTE TO REVIEWER: The indirect comparison analysis in Schering-Plough submission section 5.6 used data from the above efalizumab RCT.

The analysis updated a previous analysis, at which time the Dubertret 2006 RCT was unpublished and referred to by its conference abstract which is as follows:

Papp KA, Langley RGB, Shear NH, Sterry W, Kwon P, Dubertret L (2005a) Efficacy and safety of efalizumab therapy in high-need psoriasis patients. Presented at 63rd annual meeting of the American Academy of Dermatology, February 18-22, 2005, New Orleans, LA

At the time of submission, due to an oversight the submission's reference to Papp (2005a) was not corrected to its published equivalent nor was the correct, published reference listed in the Appendix.

- Gordon, K. B., K. A. Papp, et al. (2003). "Efalizumab for Patients with Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial." Jama **290**(23): 3073-3080.
- Lebwohl, M., S. K. Tyring, et al. (2003). "A novel targeted T-cell modulator, efalizumab, for plaque psoriasis." New England Journal of Medicine **349**(21): 2004-13.
- Leonardi, C. L., K. A. Papp, et al. (2005). "Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial." Journal of the American Academy of Dermatology **52**(3 Pt 1): 425-33.

Excluded Journal Articles

Not Adult Plaque Psoriasis (n=266)

- (2002). "Efalizumab. Anti-CD11a monoclonal antibody--Genentech/Xoma, HU 1124, hu1124, xanelim." Drugs in R & D **3**(1): 40-3.
- (2003). "Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism." Prescribe International **12**(66): 127-32.
- (2005). "Etanercept: new indication. For ankylosing spondylitis: another option." Prescribe International **14**(77): 92-3.
- (2006). "New drugs for peripheral joint psoriatic arthritis." Drug & Therapeutics Bulletin **44**(1): 1-5.
- Aboulafia, D. M., D. Bundow, et al. (2000). "Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis." Mayo Clinic Proceedings **75**(10): 1093-8.
- Abramovits, W., P. Arrazola, et al. (2004). "Enbrel (etanercept).[erratum appears in Skinmed. 2005 Jan-Feb;4(1):43 Note: Arrazola, Peter [added]]." SKINmed **3**(6): 333-5.
- Adorini, L. (2004). "A comparison of cytokine-based approaches to treat autoimmune disorders." Drug Discovery Today: Therapeutic Strategies **1**(3): 275-280.
- Af Klint, E., C. Grundtman, et al. (2005). "Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vessels." Arthritis & Rheumatism **52**(12): 3880-3889.
- Ames, S. A., C. D. Gleeson, et al. (2004). "Immune and inflammatory disorders." Nature Reviews. Drug Discovery **3**(7 SUPPL.): S18-S22.
- Amital, H., Y. H. Applbaum, et al. (2004). "SAPHO syndrome treated with pamidronate: An open-label study of 10 patients." Rheumatology **43**(5): 658-661.
- Amital, H., Y. H. Applbaum, et al. (2004). "SAPHO syndrome treated with pamidronate: an open-label study of 10 patients.[see comment]." Rheumatology **43**(5): 658-61.

- Anandarajah, A. and C. T. Ritchlin (2005). "Treatment update on spondyloarthropathy." Current Opinion in Rheumatology 17(3): 247-56.
- Anandarajah, A. P. and C. T. Ritchlin (2003). "Etanercept in psoriatic arthritis." Expert Opinion on Biological Therapy 3(1): 169-77.
- Anonymous (2002). "Efalizumab: Anti-CD11a monoclonal antibody - Genentech/Xoma, HU 1124, hu1124, Xanelim." Drugs in R & D 3(1): 40-43.
- Anonymous (2002). "Novel TNF receptor-like molecules and their biological uses." Expert Opinion on Therapeutic Patents 12(11): 1737-1739.
- Anonymous (2003). "Cdp 571." Drugs in R & D 4(3): 174-178.
- Anonymous (2003). "Useful after methotrexate failure in inflammatory rheumatism." Prescrire International 12(66): 127-132.
- Anonymous (2004). "Antibody-mediated blockade of interferon-gamma for the treatment of Crohn's disease and psoriasis." Expert Opinion on Therapeutic Patents 14(9): 1373-1378.
- Anonymous (2004). "Psoriasis of the nail." Consultant 44(4): 664.
- Anonymous (2005). "Etanercept. For ankylosing spondylitis: Another option." Prescrire International 14(77): 92-93.
- Anonymous (2005). "Leflunomide. In psoriatic rheumatism: Too many risks, too little efficacy." Prescrire International 14(78): 123-126.
- Anonymous (2006). "A look back at the pharmaceuticals market 2005. Deregulation continues." Prescrire International 15(82): 75-79.
- Anonymous (2006). "New drugs for peripheral joint psoriatic arthritis." Drug & Therapeutics Bulletin 44(1): 1-5.
- Anstey, A. V. and K. Kragballe (2006). "Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment." International Journal of Dermatology 45(8): 970-5.
- Antoni, C. and B. Manger (2002). "Infliximab for psoriasis and psoriatic arthritis." Clinical & Experimental Rheumatology 20(6 Suppl 28): S122-5.
- Antoni, C. E., A. Kavanaugh, et al. (2005). "Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)." Arthritis & Rheumatism 52(4): 1227-1236.
- Antoni, C. E., A. Kavanaugh, et al. (2005). "Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).[erratum appears in Arthritis Rheum. 2005 Sep;52(9):2951]." Arthritis & Rheumatism 52(4): 1227-36.
- Antoni, C., C. Dechant, et al. (2002). "Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation." Arthritis & Rheumatism 47(5): 506-12.
- Antoni, C., C. Dechant, et al. (2002). "Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation." Arthritis Care & Research 47(5): 506-512.
- Antoni, C., G. G. Krueger, et al. (2005). "Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial." Annals of the Rheumatic Diseases 64(8): 1150-1157.
- Antoni, C., G. G. Krueger, et al. (2005). "Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial." Annals of the Rheumatic Diseases 64(8): 1150-7.
- Bachmann, M. F. and M. R. Dyer (2004). "Therapeutic vaccination for chronic diseases: A new class of drugs in sight." Nature Reviews. Drug Discovery 3(1): 81-88.
- Badgwell, C. and T. Rosen (2007). "Cutaneous sarcoidosis therapy updated." Journal of the American Academy of Dermatology 56(1): 69-83.
- Baeten, D., E. Kruihof, et al. (2001). "Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: Histologic findings in eight patients from an open-label pilot study." Arthritis & Rheumatism 44(1): 186-195.

- Baeten, D., E. Kruithof, et al. (2003). "Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?" Annals of the Rheumatic Diseases **62**(9): 829-34.
- Ballow, M. (2006). "Biologic immune modifiers: Trials and tribulations-are we there yet?" Journal of Allergy & Clinical Immunology **118**(6): 1209-1215.
- Bansback, N. J., R. Ara, et al. (2006). "Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis." Rheumatology **45**(8): 1029-1038.
- Baraliakos, X. and J. Braun (2004). "Current concepts in the therapy of the spondyloarthritides." Biodrugs **18**(5): 307-14.
- Barnes, T., J. Goodacre, et al. (2005). "Second International Conference on Cytokine Medicines." Expert Opinion on Biological Therapy **5**(9): 1255-8.
- Barrie, A. and S. Plevy (2006). "Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab." Gastroenterology Clinics of North America **35**(4): 883-93.
- Behnam, S. M., S. E. Behnam, et al. (2005). "TNF-alpha inhibitors and congestive heart failure." SKINmed **4**(6): 363-8.
- Bernstein, C. N. (2002). "Treatment of the extraintestinal manifestations of inflammatory bowel disease." Current Gastroenterology Reports **4**(6): 513-6.
- Boehncke, W. H., M. P. Schon, et al. (2005). "Leukocyte extravasation as a target for anti-inflammatory therapy - Which molecule to choose?" Experimental Dermatology **14**(1): 70-80.
- Bondeson, J. and R. N. Maini (2001). "Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)." International Journal of Clinical Practice **55**(3): 211-6.
- Bondeson, J. and R. N. Maini (2001). "Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)." International Journal of Clinical Practice **55**(3): 211-6.
- Bonnekoh, B., Y. Malykh, et al. (2006). "Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy." European Journal of Dermatology **16**(6): 623-635.
- Brandt, J. and J. Braun (2006). "Anti-TNF-alpha agents in the treatment of psoriatic arthritis." Expert Opinion on Biological Therapy **6**(2): 99-107.
- Brandt, J., H. Haibel, et al. (2002). "Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab." Journal of Rheumatology **29**(1): 118-122.
- Brandt, J., H. Haibel, et al. (2002). "Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab." Journal of Rheumatology **29**(1): 118-22.
- Braun, J. and D. van der Heijde (2003). "Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides." Expert Opinion on Investigational Drugs **12**(7): 1097-109.
- Braun, J. and J. Sieper (2004). "Biological therapies in the spondyloarthritides--the current state." Rheumatology **43**(9): 1072-84.
- Braun, J., J. Brandt, et al. (2003). "Biologic therapies in the spondyloarthritis: new opportunities, new challenges." Current Opinion in Rheumatology **15**(4): 394-407.
- Braun, J., M. Breban, et al. (2002). "Therapy for ankylosing spondylitis: new treatment modalities." Best Practice & Research in Clinical Rheumatology **16**(4): 631-51.
- Braun, J., X. Baraliakos, et al. (2005). "Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides." Scandinavian Journal of Rheumatology **34**(3): 178-90.
- Briot, K., P. Garnero, et al. (2005). "Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor a treatment." Annals of the Rheumatic Diseases **64**(8): 1137-1140.

- Brockbank, J. and D. Gladman (2002). "Diagnosis and management of psoriatic arthritis." Drugs **62**(17): 2447-57.
- Buka, R. L. and B. B. Cunningham (2005). "Connective tissue disease in children." Pediatric Annals **34**(3): 225-238.
- Calabrese, L. (2006). "The yin and yang of tumor necrosis factor inhibitors." Cleveland Clinic Journal of Medicine **73**(3): 251-256.
- Canete, J. D., J. L. Pablos, et al. (2004). "Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis." Arthritis & Rheumatism **50**(5): 1636-41.
- Carrera, C., J. M. Mascaró, Jr., et al. (2007). "Pyoderma vegetans associated with severe psoriatic arthritis: good response to etanercept." Dermatology **214**(1): 77-81.
- Carter, J. D., J. Valeriano, et al. (2006). "Tumor necrosis factor- α inhibition and VATER association: A causal relationship?" Journal of Rheumatology **33**(5): 1014-1017.
- Carter, J. D., J. Valeriano, et al. (2006). "Tumor necrosis factor- α inhibition and VATER association: a causal relationship." Journal of Rheumatology **33**(5): 1014-7.
- Cassano, N., F. Loconsole, et al. (2006). "Infliximab in recalcitrant severe atopic eczema associated with contact allergy." International Journal of Immunopathology & Pharmacology **19**(1): 237-240.
- Cassell, S. E., J. D. Bieber, et al. (2007). "The modified Nail Psoriasis Severity Index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis." Journal of Rheumatology **34**(1): 123-129.
- Cauza, E., K. Cauza, et al. (2002). "Intravenous anti TNF- α antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis." Wiener Klinische Wochenschrift **114**(23-24): 1004-1007.
- Cauza, E., U. Hanusch-Enserer, et al. (2006). "Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein." Journal of Clinical Pharmacy & Therapeutics **31**(2): 149-52.
- Cheifetz, A. and L. Mayer (2005). "Monoclonal antibodies, immunogenicity, and associated infusion reactions." Mount Sinai Journal of Medicine **72**(4): 250-256.
- Cherouvim, E. P., E. Zintzaras, et al. (2004). "Infliximab therapy for patients with active and refractory spondyloarthropathies at the dose of 3 mg/kg: A 20-month open treatment." JCR: Journal of Clinical Rheumatology **10**(4): 162-168.
- Chou, C. T. (2006). "The clinical application of etanercept in Chinese patients with rheumatic diseases." Modern Rheumatology **16**(4): 206-213.
- Chou, C.-T. (2006). "The clinical application of etanercept in Chinese patients with rheumatic diseases." Modern Rheumatology **16**(4): 206-13.
- Clarke, J., W. Leach, et al. (2004). "Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody." Regulatory Toxicology & Pharmacology **40**(3): 219-26.
- Clayton, T. H., S. Ogden, et al. (2006). "Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab." Journal of the American Academy of Dermatology **54**(5): 892-895.
- Coffey, G. P., E. Stefanich, et al. (2004). "In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells." Journal of Pharmacology & Experimental Therapeutics **310**(3): 896-904.
- Cole, P. and X. Rabasseda (2004). "The soluble tumor necrosis factor receptor etanercept: a new strategy for the treatment of autoimmune rheumatic disease." Drugs of Today **40**(4): 281-324.
- Cordiali-Fei, P., E. Trento, et al. "Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF- α ." Journal.
- Covelli, M., C. Scioscia, et al. (2005). "Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab." Clinical & Experimental Rheumatology **23**(2): 145-51.
- Culy, C. R. and G. M. Keating (2002). "Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis." Drugs **62**(17): 2493-537.

- Culy, C. R. and G. M. Keating (2003). "Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis." *Biodrugs* **17**(2): 139-45.
- Danda, D. and K. Pile (2003). "Rheumatoid arthritis - Early management guidelines for GPs." *Medicine Today* **4**(12): 14-21.
- Daoussis, D., I. Antonopoulos, et al. (2007). "Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis." *Rheumatology* **46**(2): 227-231.
- Davis Jr, J. C., D. Van Der Heijde, et al. (2003). "Recombinant Human Tumor Necrosis Factor Receptor (Etanercept) for Treating Ankylosing Spondylitis: A Randomized, Controlled Trial." *Arthritis & Rheumatism* **48**(11): 3230-3236.
- Davis, J. C., Jr., D. Van Der Heijde, et al. (2003). "Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial." *Arthritis & Rheumatism* **48**(11): 3230-6.
- De Keyser, F., D. Baeten, et al. (2002). "Gut inflammation and spondyloarthropathies." *Current Rheumatology Reports* **4**(6): 525-32.
- De Keyser, F., D. Baeten, et al. (2004). "Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis." *Drugs* **64**(24): 2793-811.
- De Keyser, F., F. Van den Bosch, et al. (2006). "Anti-TNF-alpha therapy in ankylosing spondylitis." *Cytokine* **33**(5): 294-298.
- de Vlam, K. and R. J. U. Lories (2006). "Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study." *Rheumatology* **45**(3): 321-4.
- Delaunay, C., V. Farrenq, et al. (2005). "Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data." *Journal of Rheumatology* **32**(11): 2183-5.
- Deng, A., V. Harvey, et al. (2006). "Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor a inhibitors." *Archives of Dermatology* **142**(2): 198-202.
- Deng, A., V. Harvey, et al. (2006). "Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors." *Archives of Dermatology* **142**(2): 198-202.
- Desai, S. B. and D. E. Furst (2006). "Problems encountered during anti-tumour necrosis factor therapy." *Best Practice & Research in Clinical Rheumatology* **20**(4): 757-90.
- Dinarello, C. A. (2007). "Interleukin-18 and the Pathogenesis of Inflammatory Diseases." *Seminars in Nephrology* **27**(1): 98-114.
- Drosou, A., R. S. Kirsner, et al. (2003). "Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses." *Journal of Cutaneous Medicine & Surgery* **7**(5): 382-6.
- Drynda, S., B. Ringel, et al. (2004). "Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFa therapy." *Pathology, Research & Practice* **200**(2): 165-171.
- Ehrlich, A., T. Koch, et al. (2006). "Development and reliability testing of a standardized questionnaire to assess psoriasis phenotype." *Journal of the American Academy of Dermatology* **54**(6): 987.e1-14.
- Emery, P. and F. Ponchel (2006). "Inhibiting toll-like receptors in inflammatory disease." *Lancet* **368**(9538): 821-822.
- Esposito, M., A. Mazzotta, et al. (2006). "Treatment of erythrodermic psoriasis with etanercept." *British Journal of Dermatology* **155**(1): 156-9.
- Feldmann, M., F. M. Brennan, et al. (2004). "Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?" *Novartis Foundation Symposium* **256**: 53-69; discussion 69-73.
- Feletar, M., J. E. Brockbank, et al. (2004). "Treatment of refractory psoriatic arthritis with infliximab: A 12 month observational study of 16 patients." *Annals of the Rheumatic Diseases* **63**(2): 156-161.
- Feletar, M., J. E. Brockbank, et al. (2004). "Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.[see comment]." *Annals of the Rheumatic Diseases* **63**(2): 156-61.
- Fernandes, T. A. P., J. E. Corrente, et al. (2007). "Remission status follow-up in children with juvenile idiopathic arthritis." *Jornal de Pediatria* **83**(2): 141-148.

- Fernandez-Nebro, A., E. Tomero, et al. (2005). "Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.[erratum appears in Am J Med. 2006 Feb;119(2):191 Note: Garcia-Vicuna, Rosa [corrected to Portales, Rosa Garcia]]" American Journal of Medicine **118**(5): 552-6.
- Ferraccioli, G. F. and E. Gremese (2006). "Biological therapies in autoimmune chronic inflammatory diseases (ACIDs)." European Review for Medical & Pharmacological Sciences **10**(1): 37-40.
- Fiocco, U., F. Ferro, et al. (2005). "Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept." Annals of the Rheumatic Diseases **64**(6): 899-905.
- Fiocco, U., F. Ferro, et al. (2005). "Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept." Annals of the Rheumatic Diseases **64**(6): 899-905.
- Fiocco, U., F. Ferro, et al. (2005). "Rheumatoid and psoriatic knee synovitis: Clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept." Annals of the Rheumatic Diseases **64**(6): 899-905.
- Fitzcharles, M. A., D. Clayton, et al. (2002). "The use of infliximab in academic rheumatology practice: An audit of early clinical experience." Journal of Rheumatology **29**(12): 2525-2530.
- Fleischmann, R. and I. Iqbal (2007). "Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis." Drugs & Aging **24**(3): 239-54.
- Fleischmann, R., I. Iqbal, et al. (2002). "Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept." Drug Safety **25**(3): 173-97.
- Fleischmann, R., S. W. Baumgartner, et al. (2006). "Long term safety of etanercept in elderly subjects with rheumatic diseases." Annals of the Rheumatic Diseases **65**(3): 379-84.
- Fransen, J., C. Antoni, et al. (2006). "Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors." Annals of the Rheumatic Diseases **65**(10): 1373-1378.
- Fransen, J., C. Antoni, et al. (2006). "Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors." Annals of the Rheumatic Diseases **65**(10): 1373-8.
- Garrity, J. A., A. W. Coleman, et al. (2004). "Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab." American Journal of Ophthalmology **138**(6): 925-930.
- Garrity, J. A., A. W. Coleman, et al. (2004). "Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab.[see comment]." American Journal of Ophthalmology **138**(6): 925-30.
- George, S. J., H. L. Anderson, et al. (2006). "Adalimumab-induced urticaria." Dermatology Online Journal **12**(2).
- Giblin, P. A. and R. M. Lemieux (2006). "LFA-1 as a key regulator of immune function: approaches toward the development of LFA-1-based therapeutics." Current Pharmaceutical Design **12**(22): 2771-95.
- Gladman, D. D. (2003). "Effectiveness of psoriatic arthritis therapies." Seminars in Arthritis & Rheumatism **33**(1): 29-37.
- Gladman, D. D. (2004). "Psoriatic arthritis." Dermatologic Therapy **17**(5): 350-63.
- Godessart, N. (2005). "Chemokine receptors: attractive targets for drug discovery." Annals of the New York Academy of Sciences **1051**: 647-57.
- Goedkoop, A. Y., M. C. Kraan, et al. (2004). "Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study." Arthritis Research & Therapy **6**(4): R326-34.
- Gottlieb, A. B. (2003). "Clinical research helps elucidate the role of tumor necrosis factor- α in the pathogenesis of T_H1-mediated immune disorders: Use of targeted immunotherapeutics as pathogenic probes." Lupus **12**(3): 190-194.

- Gottlieb, A. B. (2003). "Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes." *Lupus* 12(3): 190-4.
- Gottlieb, A. B. (2003). "Psoriatic arthritis: a guide for dermatology nurses." *Dermatology Nursing* 15(2): 107-10.
- Gottlieb, A. B. and C. E. Antoni (2004). "Treating psoriatic arthritis: how effective are TNF antagonists?" *Arthritis Research & Therapy* 6 Suppl 2: S31-5.
- Grainger, R. and A. Harrison (2005). "TNF inhibitors for inflammatory arthritis in New Zealand." *New Zealand Medical Journal* 118(1224).
- Grainger, R. and A. Harrison (2005). "TNF inhibitors for inflammatory arthritis in New Zealand.[see comment]." *New Zealand Medical Journal* 118(1224): U1706.
- Gratacos, J., E. Casado, et al. (2007). "Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate." *Annals of the Rheumatic Diseases* 66(4): 493-7.
- Gross, J. B. (2004). "Nonresponders to previous chronic hepatitis C treatment." *Current Treatment Options in Gastroenterology* 7(6): 469-475.
- Hale, S. and S. Lightman (2006). "Anti-TNF therapies in the management of acute and chronic uveitis." *Cytokine* 33(4): 231-7.
- Hatemi, G., M. Melikoglu, et al. (2007). "Infliximab does not suppress the tuberculin skin test (purified protein derivative)." *Journal of Rheumatology* 34(3): 474-480.
- Hawrot, A. C., D. W. Metry, et al. (2006). "Etanercept for psoriasis in the pediatric population: experience in nine patients." *Pediatric Dermatology* 23(1): 67-71.
- Healy, P. J. and P. S. Helliwell (2006). "Dactylitis: pathogenesis and clinical considerations." *Current Rheumatology Reports* 8(5): 338-41.
- Hellmich, B. and W. L. Gross (2003). "The annual European Congress of Rheumatology: Recent advances in the treatment of rheumatic diseases." *Expert Opinion on Investigational Drugs* 12(10): 1713-1719.
- Hellmich, B. and W. L. Gross (2003). "The Annual European Congress of Rheumatology: recent advances in the treatment of rheumatic diseases. Lisbon, Portugal, June 18-21, 2003." *Expert Opinion on Investigational Drugs* 12(10): 1713-9.
- Heymann, W. R. (2007). "Antipsoriatic biologic agents for the treatment of atopic dermatitis." *Journal of the American Academy of Dermatology* 56(5): 854-855.
- Hochberg, M. C., M. G. Leibold, et al. (2005). "The benefit/risk profile of TNF-blocking agents: findings of a consensus panel." *Seminars in Arthritis & Rheumatism* 34(6): 819-36.
- Horneff, G. and R. Burgos-Vargas (2002). "TNF-a antagonists for the treatment of juvenile-onset spondyloarthritis." *Clinical & Experimental Rheumatology* 20(6 SUPPL. 28): S-137-S-142.
- Jackson, C. G. (2001). "Immunomodulating drugs in the management of psoriatic arthritis." *American Journal of Clinical Dermatology* 2(6): 367-75.
- Jansson, A., E. D. Renner, et al. (2007). "Classification of non-bacterial osteitis: Retrospective study of clinical, immunological and genetic aspects in 89 patients." *Rheumatology* 46(1): 154-160.
- Kary, S., M. Worm, et al. (2006). "New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor a antagonists." *Annals of the Rheumatic Diseases* 65(3): 405-407.
- Kavanaugh, A., C. Antoni, et al. (2006). "Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis." *Journal of Rheumatology* 33(11): 2254-9.
- Kavanaugh, A., C. Antoni, et al. (2006). "Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis." *Annals of the Rheumatic Diseases* 65(4): 471-7.
- Kavanaugh, A., C. E. Antoni, et al. (2006). "The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year." *Annals of the Rheumatic Diseases* 65(8): 1038-43.
- Kavanaugh, A., G. G. Krueger, et al. (2007). "Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: Results from the IMPACT 2 trial." *Annals of the Rheumatic Diseases* 66(4): 498-505.

- Kavanaugh, A., G. G. Krueger, et al. (2007). "Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial." Annals of the Rheumatic Diseases **66**(4): 498-505.
- Kavanaugh, A., Z. Tutuncu, et al. (2006). "Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis." Current Opinion in Rheumatology **18**(4): 347-53.
- Keat, A., N. Barkham, et al. (2005). "BSR guidelines for prescribing TNF-a blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology." Rheumatology **44**(7): 939-947.
- Keating, G. M. and C. M. Perry (2002). "Infliximab: An updated review of its use in Crohn's disease and rheumatoid arthritis." Biodrugs **16**(2): 111-148.
- Keyser, F. D., H. Mielants, et al. (2001). "Current use of biologicals for the treatment of spondyloarthropathies." Expert Opinion on Pharmacotherapy **2**(1): 85-93.
- Khanna, M., M. A. Shirodkar, et al. (2003). "Etanercept therapy in patients with autoimmunity and hepatitis C." Journal of Dermatological Treatment **14**(4): 229-32.
- Kivitz, A. and O. G. Segurado (2007). "HUMIRA pen: A novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab." Expert Review of Medical Devices **4**(2): 109-116.
- Kontinen, L., V. Honkanen, et al. (2006). "Biological treatment in rheumatic diseases: Results from a longitudinal surveillance: Adverse events." Rheumatology International **26**(10): 916-922.
- Kuenzli, S. and J. Lubbe (2002). "Dermatology." Medecine et Hygiene **60**(2375): 89-96.
- Kvien, T. K., M. S. Heiberg, et al. (2005). "A Norwegian DMARD register: Prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases." Clinical & Experimental Rheumatology **23**(5 SUPPL. 39): S188-S194.
- Kyle, S., D. Chandler, et al. (2005). "Guideline for anti-TNF-a therapy in psoriatic arthritis." Rheumatology **44**(3): 390-397.
- Lee, H. H., I. H. Song, et al. (2007). "Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-a antagonists." British Journal of Dermatology **156**(3): 486-491.
- Lee, J. H., N. R. Slifman, et al. (2002). "Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor a antagonists infliximab and etanercept." Arthritis & Rheumatism **46**(10): 2565-2570.
- Lee, J.-H., N. R. Slifman, et al. (2002). "Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept." Arthritis & Rheumatism **46**(10): 2565-70.
- Li, L., A. M. Das, et al. (2002). "What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases." Pulmonary Pharmacology & Therapeutics **15**(5): 409-16.
- Loos, T., L. Dekeyser, et al. (2006). "TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: Enhanced CXCL9 in autoimmune arthritis." Laboratory Investigation **86**(9): 902-916.
- Lurati, A., I. Pontikaki, et al. (2006). "A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor a agents." Arthritis & Rheumatism **54**(5): 1602-1607.
- Magliocco, M. A. and A. B. Gottlieb (2004). "Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 cases." Journal of the American Academy of Dermatology **51**(4): 580-584.
- Maini, S. R. (2004). "Infliximab treatment of rheumatoid arthritis." Rheumatic Diseases Clinics of North America **30**(2): 329-47.
- Maksymowych, W. P. (2002). "Novel therapies in the treatment of spondyloarthritis." Expert Opinion on Investigational Drugs **11**(7): 937-46.
- Markham, T., R. Mullan, et al. (2006). "Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy." Journal of the American Academy of Dermatology **54**(6): 1003-1012.

- Massara, A., P. L. Cavazzini, et al. (2006). "In SAPHO syndrome anti-TNF- α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations." Rheumatology **45**(6): 730-733.
- Massara, A., P. L. Cavazzini, et al. (2006). "In SAPHO syndrome anti-TNF- α therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations." Rheumatology **45**(6): 730-3.
- Mastroianni, A., E. Minutilli, et al. (2005). "Cytokine profiles during infliximab monotherapy in psoriatic arthritis." British Journal of Dermatology **153**(3): 531-6.
- Matera, M. G. and M. Cazzola (2004). "New anti-inflammatory approaches in COPD." Drug Discovery Today: Therapeutic Strategies **1**(3): 335-343.
- McCormack, P. L. and K. Wellington (2004). "Etanercept: in ankylosing spondylitis." Biodrugs **18**(3): 199-205; discussion 206.
- Mease, P. (2002). "Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept." Clinical & Experimental Rheumatology **20**(6 Suppl 28): S116-21.
- Mease, P. J. (2001). "Cytokine blockers in psoriatic arthritis." Annals of the Rheumatic Diseases **60** Suppl 3: iii37-40.
- Mease, P. J. (2002). "Etanercept: a new era in the treatment of psoriatic arthritis." American Journal of Managed Care **8**(6 Suppl): S181-93.
- Mease, P. J. (2003). "Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment." Current Opinion in Rheumatology **15**(3): 205-12.
- Mease, P. J. (2004). "Targeting therapy in psoriatic arthritis." Drug Discovery Today: Therapeutic Strategies **1**(3): 389-396.
- Mease, P. J. (2005). "Psoriatic arthritis therapy advances." Current Opinion in Rheumatology **17**(4): 426-32.
- Mease, P. J. and C. E. Antoni (2005). "Psoriatic arthritis treatment: biological response modifiers." Annals of the Rheumatic Diseases **64** Suppl 2: ii78-82.
- Mease, P. J., A. J. Kivitz, et al. (2004). "Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression." Arthritis & Rheumatism **50**(7): 2264-72.
- Mease, P. J., A. J. Kivitz, et al. (2006). "Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept." Journal of Rheumatology **33**(4): 712-721.
- Mease, P. J., A. J. Kivitz, et al. (2006). "Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.[see comment]." Journal of Rheumatology **33**(4): 712-21.
- Mease, P. J., B. S. Goffe, et al. (2000). "Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial." Lancet **356**(9227): 385-390.
- Mease, P. J., C. T. Ritchlin, et al. (2004). "Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept." Journal of Rheumatology **31**(7): 1356-1361.
- Mease, P. J., C. T. Ritchlin, et al. (2004). "Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.[see comment]." Journal of Rheumatology **31**(7): 1356-61.
- Mease, P. J., D. D. Gladman, et al. (2006). "Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study." Arthritis & Rheumatism **54**(5): 1638-1645.
- Militello, G., A. Xia, et al. (2006). "Etanercept for the treatment of psoriasis in the elderly." Journal of the American Academy of Dermatology **55**(3): 517-9.
- Moen, K., J. G. Brun, et al. (2006). "Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs." Clinical & Experimental Rheumatology **24**(6): 656-663.
- Mok, C. C. (2006). "Consensus on the use and monitoring of anti-TNF- α therapies for rheumatic diseases in Hong Kong 2005." APLAR Journal of Rheumatology **9**(2): 175-180.
- Mpofu, S., L. S. Teh, et al. (2003). "Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy." Rheumatology **42**(2): 362-366.

- Nash, P. (2006). "Anti-tumor necrosis factor therapy: The Australian experience." APLAR Journal of Rheumatology 9(2): 119-123.
- Nash, P. T. and T. H. J. Florin (2005). "Tumour necrosis factor inhibitors." Medical Journal of Australia 183(4): 205-8.
- Navarra, S. V., A. A. Raso, et al. (2006). "Clinical experience with infliximab among Filipino patients with rheumatic diseases." APLAR Journal of Rheumatology 9(2): 150-156.
- Olivieri, I., A. Padula, et al. (2006). "Pharmacological management of SAPHO syndrome." Expert Opinion on Investigational Drugs 15(10): 1229-33.
- Orenstein, R. and E. L. Matteson (2006). "TNF inhibitors and infections." Infections in Medicine 23(3): 99-114.
- Ornetti, P., H. Chevillotte, et al. (2006). "Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients." Drugs & Aging 23(11): 855-60.
- Padoa, C. J. and N. J. Crowther (2006). "Engineered antibodies: A new tool for use in diabetes research." Diabetes Research & Clinical Practice 74(2 SUPPL.): S51-S62.
- Paleolog, E. (2001). "Anti-TNF α in the treatment of inflammatory diseases." Central-European Journal of Immunology 26(3): 140-148.
- Pardi, D. S., V. R. Ramnath, et al. (2002). "Lymphocytic colitis: Clinical features, treatment, and outcomes." American Journal of Gastroenterology 97(11): 2829-2833.
- Passo, M. (2006). "Emerging therapies in juvenile rheumatoid/idiopathic arthritis." Current Problems in Pediatric & Adolescent Health Care 36(3): 97-103.
- Peloso, P. M. and J. Braun (2004). "Expanding the armamentarium for the spondyloarthropathies." Arthritis Research & Therapy 6 Suppl 2: S36-43.
- Pereira, T. M., A. P. Vieira, et al. (2006). "Anti-TNF-alpha therapy in childhood pustular psoriasis." Dermatology 213(4): 350-2.
- Pham, T., F. Guillemin, et al. (2006). "TNF α antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology." Joint, Bone, Spine: Revue du Rhumatisme 73(5): 547-553.
- Phillips, K., M. E. Husni, et al. (2002). "Experience with etanercept in an academic medical center: Are infection rates increased?" Arthritis Care & Research 47(1): 17-21.
- Phillips, K., M. E. Husni, et al. (2002). "Experience with etanercept in an academic medical center: are infection rates increased?[see comment]." Arthritis & Rheumatism 47(1): 17-21.
- Pincelli, C., E. Henninger, et al. (2006). "The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: Pooled analysis of data from Phase III clinical trials of efalizumab." Archives of Dermatological Research 298(7): 329-338.
- Quigley, E. (2006). "Cell adhesion molecules as therapeutic targets: Interview with Professor Michael P Schon." Expert Opinion on Therapeutic Targets 10(6): 799-802.
- Reimold, A. M. (2002). "TNF α as therapeutic target: new drugs, more applications." Current Drug Targets - Inflammation & Allergy 1(4): 377-92.
- Reimold, A. M. (2003). "New indications for treatment of chronic inflammation by TNF-alpha blockade." American Journal of the Medical Sciences 325(2): 75-92.
- Rinaldi, F., G. Provenzano, et al. (2005). "Long term infliximab treatment for severe psoriatic arthritis: Evidence of sustained clinical and radiographic response." Annals of the Rheumatic Diseases 64(9): 1375-1376.
- Ritchlin, C. (2006). "Efficacy and safety of infliximab for the treatment of psoriatic arthritis." Nature Clinical Practice Rheumatology 2(6): 300-1.
- Ritchlin, C. T. (2006). "The efficacy and safety of alefacept in psoriatic arthritis." Current Rheumatology Reports 8(5): 330-331.
- Romano, S. J. (2005). "Selectin antagonists: Therapeutic potential in asthma and COPD." Treatments in Respiratory Medicine 4(2): 85-94.

- Rongioletti, F., M. Borenstein, et al. (2003). "Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab." Journal of Dermatological Treatment **14**(4): 222-5.
- Rosenbaum, J. T. and J. R. Smith (2002). "Anti-TNF therapy for eye involvement in spondyloarthropathy." Clinical & Experimental Rheumatology **20**(6 SUPPL. 28): S-143-S-145.
- Salvarani, C., F. Cantini, et al. (2002). "Disease-modifying antirheumatic drug therapy for psoriatic arthritis." Clinical & Experimental Rheumatology **20**(6 SUPPL. 28): S-71-S-75.
- Salvarani, C., F. Cantini, et al. (2003). "Efficacy of infliximab in resistant psoriatic arthritis." Arthritis & Rheumatism **49**(4): 541-5.
- Salvarani, C., F. Cantini, et al. (2003). "Efficacy of infliximab in resistant psoriatic arthritis." Arthritis Care & Research **49**(4): 541-545.
- Salvarani, C., I. Olivieri, et al. (2006). "Recommendations of the Italian society for rheumatology for the use of biologic (TNF-a blocking) agents in treatment of psoriatic arthritis." Clinical & Experimental Rheumatology **24**(1): 70-78.
- Sanchez, A. J. and D. J. Boken (2004). "Isoniazid-associated pancreatitis." Infections in Medicine **21**(12): 622-623.
- Saurenmann, R. K., A. V. Levin, et al. (2006). "Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFa agents." Journal of Pediatrics **149**(6): 833-836.
- Scali, J. J., A. Kaminsky, et al. (2005). "Open-label 24-month study evaluating infliximab therapy in patients with psoriatic spondyloarthropathy." Annals of the New York Academy of Sciences **1051**: 543-50.
- Scallon, B., A. Cai, et al. (2002). "Binding and functional comparisons of two types of tumor necrosis factor antagonists." Journal of Pharmacology & Experimental Therapeutics **301**(2): 418-426.
- Scallon, B., A. Cai, et al. (2002). "Binding and functional comparisons of two types of tumor necrosis factor antagonists." Journal of Pharmacology & Experimental Therapeutics **301**(2): 418-26.
- Scheinfeld, N. (2006). "Efalizumab: a review of events reported during clinical trials and side effects." Expert Opinion on Drug Safety **5**(2): 197-209.
- Schwartzman, S., R. Fleischmann, et al. (2004). "Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?" Arthritis Research & Therapy **6 Suppl 2**: S3-S11.
- Scott, D. L. (2005). "Etanercept in arthritis." International Journal of Clinical Practice **59**(1): 114-8.
- Scott, D. L. (2005). "Etanercept in arthritis." International Journal of Clinical Practice **59**(1): 114-8.
- Seitz, M., U. Wirthmuller, et al. (2007). "The -308 tumour necrosis factor-a gene polymorphism predicts therapeutic response to TNFa-blockers in rheumatoid arthritis and spondyloarthritis patients." Rheumatology **46**(1): 93-96.
- Selenko-Gebauer, N., F. Karlhofer, et al. (2007). "Efalizumab in routine use: A clinical experience." British Journal of Dermatology **156**(SUPPL. 2): 1-6.
- Sellam, J., B. Bouvard, et al. (2007). "Use of infliximab to treat psoriatic arthritis in HIV-positive patients." Joint, Bone, Spine: Revue du Rhumatisme **74**(2): 197-200.
- Sellam, J., Y. Allanore, et al. (2005). "Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate." Joint, Bone, Spine: Revue du Rhumatisme **72**(1): 48-52.
- Shatin, D., N. S. B. Rawson, et al. (2006). "Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions." Pharmacoepidemiology & Drug Safety **15**(1): 11-18.
- Sidiropoulos, P., H. D. Kritikos, et al. (2005). "Low dose of infliximab is inadequate in most patients with spondylarthropathies." Clinical & Experimental Rheumatology **23**(4): 513-6.
- Sieper, J. and J. Braun (2001). "New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy." Annals of the Rheumatic Diseases **60 Suppl 3**: iii58-61.
- Singh, J. and A. Suruchi (2004). "AntiTNF-a strategy: Present status of this therapeutic paradigm." Indian Journal of Pharmacology **36**(1): 10-14.
- Slifman, N. R., S. K. Gershon, et al. (2003). "Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents." Arthritis & Rheumatism **48**(2): 319-24.

- Smith, J. R., R. D. Levinson, et al. (2001). "Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease." Arthritis & Rheumatism **45**(3): 252-7.
- Sokka, T., J. Willoughby, et al. (2003). "Databases of patients with early rheumatoid arthritis in the USA." Clinical & Experimental Rheumatology **21**(5 SUPPL. 31): S146-S153.
- Sorbera, L. A., P. A. Leeson, et al. (2001). "hu1124. Antipsoriatic, treatment of transplant rejection." Drugs of the Future **26**(3): 232-238.
- Soriano, E. R. and N. J. McHugh (2006). "Therapies for peripheral joint disease in psoriatic arthritis. A systematic review." Journal of Rheumatology **33**(7): 1422-30.
- Spanakis, E., P. Sidiropoulos, et al. (2006). "Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab." Journal of Rheumatology **33**(12): 2440-6.
- Spencer-Green, G. (2000). "Etanercept (Enbrel): update on therapeutic use." Annals of the Rheumatic Diseases **59** Suppl 1: i46-9.
- St Clair, E. W. (2002). "Infliximab treatment for rheumatic disease: clinical and radiological efficacy." Annals of the Rheumatic Diseases **61** Suppl 2: ii67-9.
- Stabile, A., L. Avallone, et al. (2006). "Focus on juvenile idiopathic arthritis according to the 2001 Edmonton revised classification from the International League of Associations for Rheumatology: An Italian experience." European Review for Medical & Pharmacological Sciences **10**(5): 229-234.
- Starmans-Kool, M. J. F., H. R. M. Peeters, et al. (2005). "Pustular skin lesions in patients treated with infliximab: report of two cases." Rheumatology International **25**(7): 550-2.
- Stewart, M. W., S. Alvarez, et al. (2006). "Visual recovery following Mycobacterium chelonae endophthalmitis." Ocular Immunology & Inflammation **14**(3): 181-3.
- Stoeckman, A. K., E. C. Baechler, et al. (2006). "A distinct inflammatory gene expression profile in patients with psoriatic arthritis." Genes & Immunity **7**(7): 583-591.
- Stokes, D. G. and J. M. Kremer (2003). "Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.[see comment]." Seminars in Arthritis & Rheumatism **33**(1): 1-18.
- Sulit, D. J. and J. E. Clarke (2005). "Psoriatic arthritis in a military aviator." Aviation Space & Environmental Medicine **76**(7): 684-8.
- Sullivan, T. P., E. Welsh, et al. (2003). "Infliximab for hidradenitis suppurativa." British Journal of Dermatology **149**(5): 1046-9.
- Szalai, C., E. I. Buzas, et al. (2006). "Genomic strategies in pharmacology of asthma and autoimmunity." Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry **5**(4): 383-399.
- Szodoray, P., P. Alex, et al. (2007). "Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system." Rheumatology **46**(3): 417-425.
- Tektonidou, M. G., J. Serelis, et al. (2007). "Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment." Clinical Rheumatology **26**(2): 258-260.
- Theodossiadis, P. G., N. N. Markomichelakis, et al. (2007). "Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation." Retina **27**(4): 399-413.
- Ting, P. T. and J. Y. Koo (2006). "Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients." International Journal of Dermatology **45**(6): 689-92.
- Trevillian, P. (2006). "Immunosuppressants - Clinical applications." Australian Prescriber **29**(4): 102-108.
- Tutuncu, Z., G. J. Morgan Jr, et al. (2002). "Anti-TNF therapy for other inflammatory conditions." Clinical & Experimental Rheumatology **20**(6 SUPPL. 28): S-146-S-151.
- Tutuncu, Z., G. J. Morgan, Jr., et al. (2002). "Anti-TNF therapy for other inflammatory conditions." Clinical & Experimental Rheumatology **20**(6 Suppl 28): S146-51.
- Van den Bosch, F., E. Kruithof, et al. (2000). "Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthritis: an open pilot study.[see comment]." Annals of the Rheumatic Diseases **59**(6): 428-33.

- Wagner, A. D., J. Andresen, et al. (2002). "Sustained response to tumor necrosis factor a-blocking agents in two patients with SAPHO syndrome." Arthritis & Rheumatism **46**(7): 1965-1968.
- Westra, J. and P. C. Limburg (2006). "p38 Mitogen-activated protein kinase (MAPK) in rheumatoid arthritis." Mini-Reviews in Medicinal Chemistry **6**(8): 867-874.
- Williams, J. D. L. and C. E. M. Griffiths (2002). "Cytokine blocking agents in dermatology." Clinical & Experimental Dermatology **27**(7): 585-90.
- Wollina, U. and H. Konrad (2002). "Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-a antibody." Journal of the European Academy of Dermatology & Venereology **16**(2): 127-129.
- Wollina, U. and H. Konrad (2002). "Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody." Journal of the European Academy of Dermatology & Venereology **16**(2): 127-9.
- Wong, V. K. and M. G. Lebwohl (2005). "Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist." Expert Opinion on Biological Therapy **5**(11): 1505-13.
- Wu, B., A. Joshi, et al. (2006). "The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab." Journal of Pharmaceutical Sciences **95**(6): 1258-68.
- Yazici, Y., D. Erkan, et al. (2000). "A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.[see comment]." Clinical & Experimental Rheumatology **18**(6): 732-4.
- Yoon, C. H. and H. Y. Kim (2006). "Extended indications for anti-tumor necrosis factor-a therapy." APLAR Journal of Rheumatology **9**(2): 193-199.

Not an efficacy RCT involving licensed infliximab, etanercept or efalizumab (n=168)

- (2003). "Efalizumab (Raptiva) for treatment of psoriasis.[erratum appears in Med Lett Drugs Ther. 2004 Jan 19;46(1174):8]." Medical Letter on Drugs & Therapeutics **45**(1171): 97-8.
- (2006). "Efalizumab: new drug. Plaque psoriasis: too many unknowns." Prescribe International **15**(81): 8-11.
- Ahmad, K. and S. Rogers (2007). "Two years of experience with etanercept in recalcitrant psoriasis." British Journal of Dermatology **156**(5): 1010-1014.
- Alexis, A. F. and B. E. Strober (2005). "Off-label dermatologic uses of anti-TNF-a therapies." Journal of Cutaneous Medicine & Surgery **9**(6): 296-302.
- Al-Salem, I. H. (2003). "Striking and rapid improvement of plaque psoriasis with infliximab. A report of two cases." Dermatology **207**(1): 54-6.
- Atzeni, F., P. Sarzi-Puttini, et al. (2005). "Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review." Autoimmunity Reviews **4**(3): 144-52.
- Baumer, W., J. Hoppmann, et al. (2007). "Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis." Inflammation & Allergy Drug Targets **6**(1): 17-26.
- Bhosle, M. J., S. R. Feldman, et al. (2006). "Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis." Journal of Dermatological Treatment **17**(5): 294-301.
- Boehncke, W. H., R. A. Brasie, et al. (2006). "Recommendations for the use of etanercept in psoriasis: A European dermatology expert group consensus." Journal of the European Academy of Dermatology & Venereology **20**(8): 988-998.
- Bohjanen, K. A. and S. E. Prawer (2004). "New biologic therapies for psoriatic disease." Minnesota Medicine **87**(3): 34-6.
- Bonnekoh, B., R. Bockelmann, et al. (2007). "The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay." Skin Pharmacology & Physiology **20**(2): 96-111.
- Braun, J. and J. Sieper (2003). "Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases." Expert Opinion on Biological Therapy **3**(1): 141-68.
- Callen, J. P. and J. H. Jackson (2005). "Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent." Journal of Dermatological Treatment **16**(5-6): 350-2.

- Carey, W., S. Glazer, et al. (2006). "Relapse, rebound, and psoriasis adverse events: an advisory group report." Journal of the American Academy of Dermatology 54(4 Suppl 1): S171-81.
- Carlin, C. S., S. R. Feldman, et al. (2004). "A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis." Journal of the American Academy of Dermatology 50(6): 859-866.
- Cassano, N., F. Loconsole, et al. (2004). "Infliximab monotherapy for refractory psoriasis: preliminary results." International Journal of Immunopathology & Pharmacology 17(3): 373-80.
- Cassano, N., F. Loconsole, et al. (2006). "Once-weekly administration of high-dosage Etanercept in patients with plaque psoriasis: results of a pilot experience (power study)." International Journal of Immunopathology & Pharmacology 19(1): 225-9.
- Cather, J. C. and A. Menter (2005). "Combining traditional agents and biologics for the treatment of psoriasis." Seminars in Cutaneous Medicine & Surgery 24(1): 37-45.
- Cather, J. C. and A. Menter (2005). "Efalizumab: continuous therapy for chronic psoriasis." Expert Opinion on Biological Therapy 5(3): 393-403.
- Cather, J. C., J. C. Cather, et al. (2003). "Investigational therapies for psoriasis." Journal of the American Academy of Dermatology 49(2 Suppl): S133-8.
- Cather, J. C., J. C. Cather, et al. (2003). "Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab." Expert Opinion on Biological Therapy 3(2): 361-70.
- Cauza, E., M. Spak, et al. (2002). "Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab." Rheumatology International 22(6): 227-32.
- Cecchi, R. and L. Bartoli (2006). "Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept)." Dermatology Online Journal 12(7): 4.
- Chan, J. J. and K. Gebauer (2003). "Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab)." Australasian Journal of Dermatology 44(2): 116-20.
- Cianci, R., G. Cammarota, et al. (2005). "The impact of biological agents interfering with receptor/ligand binding in the immune system." European Review for Medical & Pharmacological Sciences 9(6): 305-314.
- Clark, C. (2005). "Management of severe psoriasis." Pharmaceutical Journal 274(7352): 689-692.
- Costanzo, A., K. Peris, et al. (2007). "Long-term treatment of plaque psoriasis with efalizumab: An Italian experience." British Journal of Dermatology 156(SUPPL. 2): 17-23.
- de Groot, M., M. Appelman, et al. (2006). "Initial experience with routine administration of etanercept in psoriasis." British Journal of Dermatology 155(4): 808-14.
- Della Croce, C., V. K. Wong, et al. (2004). "Efalizumab in the treatment of psoriasis." Therapy 1(2): 197-202.
- Doggett, S. A. (2004). "Efalizumab for psoriasis?" Expert Opinion on Investigational Drugs 13(5): 551-554.
- Dubin, D. B., W. Tanner, et al. (2003). "Biologics for psoriasis. Market indicators." Nature Reviews. Drug Discovery 2(11): 855-856.
- Elewski, B., C. Leonardi, et al. (2007). "Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis." British Journal of Dermatology 156(1): 138-42.
- Feldman, S. R., R. Garton, et al. (2003). "Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and cost.[erratum appears in Expert Opin Pharmacother. 2003 Oct;4(10):1887]." Expert Opinion on Pharmacotherapy 4(9): 1525-33.
- Ferrandiz, C. and J. M. Carrascosa (2007). "Managing moderate-to-severe psoriasis with efalizumab: Experience at a single Spanish institute." British Journal of Dermatology 156(SUPPL. 2): 24-29.
- Finlay, A. Y. and J.-P. Ortonne (2004). "Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy." Journal of Cutaneous Medicine & Surgery 8(5): 310-20.
- Fisher, V. S. (2005). "Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis." Journal of Managed Care Pharmacy 11(1): 33-55.
- Gach, J. E. and J. Berth-Jones (2003). "Successful treatment of recalcitrant psoriasis with a combination of infliximab and hydroxyurea." Journal of Dermatological Treatment 14(4): 226-8.

- Galadari, H., B. Fuchs, et al. (2003). "Newly available treatments for psoriatic arthritis and their impact on skin psoriasis." International Journal of Dermatology **42**(3): 231-7.
- Girolomoni, G. and D. Abeni (2001). "Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis." Archives of Dermatology **137**(6): 784-5.
- Gisoni, P., E. Gubinelli, et al. (2004). "Targeting tumor necrosis factor-alpha in the therapy of psoriasis." Current Drug Targets - Inflammation & Allergy **3**(2): 175-83.
- Gisoni, P., M. D. Giglio, et al. (2006). "Effective management of psoriasis symptom worsening during efalizumab therapy without discontinuing treatment: a case study." Journal of Dermatological Treatment **17**(3): 172-5.
- Goedkoop, A. Y., M. C. Kraan, et al. (2004). "Early effects of tumour necrosis factor a blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis." Annals of the Rheumatic Diseases **63**(7): 769-773.
- Goffe, B. (2004). "Etanercept (Enbrel) -- an update." Skin Therapy Letter **9**(10): 1-4.
- Goffe, B. and J. C. Cather (2003). "Etanercept: An overview." Journal of the American Academy of Dermatology **49**(2 Suppl): S105-11.
- Goffe, B. S. (2004). "Disseminated granuloma annulare resolved with the T-cell modulator efalizumab." Archives of Dermatology **140**(10): 1287-1288.
- Goldsmith, D. R. and A. J. Wagstaff (2005). "Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis." American Journal of Clinical Dermatology **6**(2): 121-36.
- Goldsmith, D. R. and A. J. Wagstaff (2005). "Spotlight on etanercept in plaque psoriasis and psoriatic arthritis." Biodrugs **19**(6): 401-3.
- Gonzalez-Chavez, J. R., A. C. Berlingeri-Ramos, et al. (2005). "Puerto Rico psoriasis study group: efficacy and safety of etanercept." Journal of Drugs in Dermatology: JDD **4**(6): 735-9.
- Gordon, K. B., A. B. Gottlieb, et al. (2006). "Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy." Journal of Dermatological Treatment **17**(1): 9-17.
- Gordon, K., N. Korman, et al. (2006). "Efficacy of etanercept in an integrated multistudy database of patients with psoriasis." Journal of the American Academy of Dermatology **54**(3 Suppl 2): S101-11.
- Gottlieb, A. B. (2003). "Infliximab for psoriasis." Journal of the American Academy of Dermatology **49**(2 Suppl): S112-7.
- Gottlieb, A. B. (2004). "Etanercept for the treatment of psoriasis and psoriatic arthritis." Dermatologic Therapy **17**(5): 401-8.
- Gottlieb, A. B., C. E. M. Griffiths, et al. (2005). "Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: A double-blind, multicentre, randomized, dose-finding trial." British Journal of Dermatology **152**(6): 1219-1227.
- Gottlieb, A. B., C. L. Leonardi, et al. (2006). "Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database." Journal of the American Academy of Dermatology **54**(3 Suppl 2): S92-100.
- Gottlieb, A. B., F. Chamian, et al. (2005). "TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques." Journal of Immunology **175**(4): 2721-2729.
- Gottlieb, A. B., J. G. Krueger, et al. (2002). "Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody." Archives of Dermatology **138**(5): 591-600.
- Gottlieb, A. B., K. B. Gordon, et al. (2004). "Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis." Journal of Drugs in Dermatology: JDD **3**(6): 614-24.
- Gottlieb, A. B., P. J. Mease, et al. (2006). "Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices." Journal of Dermatological Treatment **17**(5): 279-287.
- Gottlieb, A. B., S. Masud, et al. (2003). "Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-a monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris." Journal of the American Academy of Dermatology **48**(1): 68-75.

- Gottlieb, A. B., S. Masud, et al. (2003). "Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris." Journal of the American Academy of Dermatology **48**(1): 68-75.
- Gottlieb, A. B., T. Hamilton, et al. (2006). "Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial." Journal of the American Academy of Dermatology **54**(4 SUPPL.): S154-S163.
- Gottlieb, A. B., U. Chaudhari, et al. (2003). "The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison." Journal of Drugs in Dermatology: JDD **2**(3): 260-6.
- Graves, J. E., K. Nunley, et al. (2007). "Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)." Journal of the American Academy of Dermatology **56**(1): e55-79.
- Griffiths, C. E. M. (2003). "The immunological basis of psoriasis." Journal of the European Academy of Dermatology & Venereology **17**(SUPPL. 2): 1-5.
- Guenther, L., R. G. Langley, et al. (2004). "Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004." Journal of Cutaneous Medicine & Surgery **8**(5): 321-37.
- Gurmin, V., R. Mediwake, et al. (2002). "Psoriasis: Response to high-dose intravenous immunoglobulin in three patients." British Journal of Dermatology **147**(3): 554-557.
- Hamilton, T. K. (2005). "Clinical considerations of efalizumab therapy in patients with psoriasis." Seminars in Cutaneous Medicine & Surgery **24**(1): 19-27.
- Hamminga, E. A., A. J. van der Lely, et al. (2006). "Chronic inflammation in psoriasis and obesity: Implications for therapy." Medical Hypotheses **67**(4): 768-773.
- Hutmacher, M. M., I. Nestorov, et al. (2007). "Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis." Journal of Clinical Pharmacology **47**(2): 238-48.
- Iyer, S., P. Yamauchi, et al. (2002). "Etanercept for severe psoriasis and psoriatic arthritis: Observations on combination therapy." British Journal of Dermatology **146**(1): 118-121.
- Jacob, S. E., A. Sergay, et al. (2005). "Etanercept and psoriasis, from clinical studies to real life." International Journal of Dermatology **44**(8): 688-91.
- Joshi, A., R. Bauer, et al. (2006). "An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis." Journal of Clinical Pharmacology **46**(1): 10-20.
- Jullien, D., J. C. Prinz, et al. (2004). "T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action." Dermatology **208**(4): 297-306.
- Kalb, R. E. and J. Gurske (2005). "Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo." Journal of the American Academy of Dermatology **53**(4): 616-22.
- Kleyn, C. E. and C. E. M. Griffiths (2006). "Infliximab for the treatment of psoriasis." Expert Opinion on Biological Therapy **6**(8): 797-805.
- Koo, J. and P. Khera (2005). "Update on the mechanisms and efficacy of biological therapies for psoriasis." Journal of Dermatological Science **38**(2): 75-87.
- Koo, J. and R. Wenner (2004). "Efficacy of PUVA phototherapy compared with biologics." Cosmetic Dermatology **17**(11 SUPPL. 3): 11-15.
- Koo, J., E. Lee, et al. (2004). "Psoriasis." Journal of the American Academy of Dermatology **50**(4): 613-622.
- Koo, J., S. E. Behnam, et al. (2003). "The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis." Expert Opinion on Pharmacotherapy **4**(12): 2347-2354.
- Kovarik, J. M. and P. Burtin (2003). "Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases." Expert Opinion on Emerging Drugs **8**(1): 47-62.
- Kragballe, K. (2007). "Efalizumab in the treatment of chronic plaque psoriasis: Experiences from the largest psoriasis treatment centre in Denmark." British Journal of Dermatology **156**(SUPPL. 2): 7-11.

- Krueger, G. and K. Callis (2004). "Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis." Archives of Dermatology **140**(2): 218-25.
- Krueger, G. G., B. Elewski, et al. (2006). "Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial." Journal of the American Academy of Dermatology **54**(3 Suppl 2): S112-9.
- Krueger, G. G., R. G. Langley, et al. (2005). "Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial." British Journal of Dermatology **153**(6): 1192-9.
- Kruger-Krasagakis, S., V. K. Galanopoulos, et al. (2006). "Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis." British Journal of Dermatology **154**(3): 460-466.
- LaDuca, J. R. and A. A. Gaspari (2001). "Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases." Dermatologic Clinics **19**(4): 617-35.
- Langley, R. G. B., W. P. Carey, et al. (2005). "Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience." Clinical Therapeutics **27**(9): 1317-28.
- Langley, R. G., V. Ho, et al. (2006). "Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches." Journal of Cutaneous Medicine & Surgery **9 Suppl 1**: 18-25.
- Laustsen, G. and L. Wimett (2004). "Drug approval highlights for 2003." Nurse Practitioner **29**(2): 8-15.
- Lebwohl, M. (2003). "Combining the new biologic agents with our current psoriasis armamentarium." Journal of the American Academy of Dermatology **49**(2 Suppl): S118-24.
- Lebwohl, M. (2003). "Psoriasis." Lancet **361**(9364): 1197-204.
- Lebwohl, M. (2005). "A clinician's paradigm in the treatment of psoriasis." Journal of the American Academy of Dermatology **53**(1 SUPPL.): S59-S69.
- Lebwohl, M., S. K. Tyring, et al. (2003). "A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis." New England Journal of Medicine **349**(21): 2004-2013.
- Leon, A., A. Nguyen, et al. (2007). "An attempt to formulate an evidence-based strategy in the management of moderate-to-severe psoriasis: a review of the efficacy and safety of biologics and prebiologic options." Expert Opinion on Pharmacotherapy **8**(5): 617-32.
- Leonardi, C. L. (2003). "Efalizumab: an overview." Journal of the American Academy of Dermatology **49**(2 Suppl): S98-104.
- Leonardi, C. L. (2004). "Current concepts and review of efalizumab in the treatment of psoriasis." Dermatologic Clinics **22**(4): 427-35.
- Leonardi, C. L. (2004). "Efalizumab in the treatment of psoriasis." Dermatologic Therapy **17**(5): 393-400.
- Leonardi, C. L., D. Toth, et al. (2006). "A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis." Dermatology **213**(3): 204-14.
- Lizzul, P. F., A. Aphale, et al. (2005). "Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept." Journal of Investigative Dermatology **124**(6): 1275-83.
- Lowes, M. A., F. Chamian, et al. (2005). "Increase in TNF-a and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)." Proceedings of the National Academy of Sciences of the United States of America **102**(52): 19057-19062.
- Luba, K. M. and D. L. Stulberg (2006). "Chronic plaque psoriasis." American Family Physician **73**(4): 636-644.
- Lynde, C. (2006). "Efalizumab: integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis." Journal of Cutaneous Medicine & Surgery **9 Suppl 1**: 1-3.
- Malaviya, R., Y. Sun, et al. (2006). "Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients." Journal of the American Academy of Dermatology **55**(4): 590-597.
- Marecki, S. and P. Kirkpatrick (2004). "Efalizumab." Nature Reviews Drug Discovery **3**(6): 473-4.
- Mease, P. J. (2003). "Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis." Skin Therapy Letter **8**(1): 1-4.

- Moore, A., K. B. Gordon, et al. (2007). "A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis." Journal of the American Academy of Dermatology **56**(4): 598-603.
- Mortensen, D. L., P. A. Walicke, et al. (2005). "Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis." Journal of Clinical Pharmacology **45**(3): 286-98.
- Mrowietz, U., J. T. Elder, et al. (2006). "The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients." Archives of Dermatological Research **298**(7): 309-319.
- Myers, W. A., A. B. Gottlieb, et al. (2006). "Psoriasis and psoriatic arthritis: clinical features and disease mechanisms." Clinics in Dermatology **24**(5): 438-447.
- Najarian, D. J. and A. B. Gottlieb (2003). "Connections between psoriasis and Crohn's disease." Journal of the American Academy of Dermatology **48**(6): 805-21; quiz 822-4.
- Neimann, A. L., R. L. Hodinka, et al. (2006). "Epstein-Barr virus and human herpesvirus type 6 infection in patients with psoriasis." European Journal of Dermatology **16**(5): 548-552.
- Nestorov, I., R. Zitnik, et al. (2005). "Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis." Journal of Pharmacokinetics & Pharmacodynamics **31**(6): 463-490.
- Nestorov, I., R. Zitnik, et al. (2006). "Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis." British Journal of Clinical Pharmacology **62**(4): 435-45.
- Newland, M. R., A. Weinstein, et al. (2002). "Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type." International Journal of Dermatology **41**(7): 449-52.
- Ng, C. M., A. Joshi, et al. (2005). "Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis." Pharmaceutical Research **22**(7): 1088-100.
- Ogilvie, A. L. J., M. Luftl, et al. (2006). "Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R p60 in psoriatic skin is driven by TNF-a." International Journal of Immunopathology & Pharmacology **19**(2): 271-278.
- Ogilvie, A. L., C. Antoni, et al. (2001). "Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate." British Journal of Dermatology **144**(3): 587-9.
- Papp, K. A. (2004). "Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator." Drugs of Today **40**(11): 889-99.
- Papp, K. A. (2004). "Etanercept in psoriasis." Expert Opinion on Pharmacotherapy **5**(10): 2139-46.
- Papp, K. A. and E. Henninger "Evaluation of efalizumab using safe psoriasis control." Journal.
- Papp, K. A. and E. Henninger (2005). "Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatment." Journal of Cutaneous Medicine & Surgery **9**(6): 276-83.
- Papp, K. A. and E. Henninger (2006). "Evaluation of efalizumab using safe psoriasis control." BMC Dermatology **6**: 8.
- Papp, K. A., B. Miller, et al. (2006). "Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis." Journal of the American Academy of Dermatology **54**(4 Suppl 1): S164-70.
- Papp, K. A., B. Miller, et al. (2006). "Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis." Journal of the American Academy of Dermatology **54**(4 SUPPL.): S164-S170.
- Papp, K. A., C. Camisa, et al. (2005). "Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part II." Journal of Cutaneous Medicine & Surgery **9**(6): 313-23.
- Papp, K. A., D. Toth, et al. "Approaches to discontinuing efalizumab: An open-label study of therapies for managing inflammatory recurrence." Journal.
- Papp, K. A., D. Toth, et al. (2006). "Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence." BMC Dermatology **6**: 9.

- Papp, K. A., R. Bressinck, et al. (2006). "Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial." International Journal of Dermatology 45(5): 605-14.
- Pariser, D. M. (2003). "Management of moderate to severe plaque psoriasis with biologic therapy." Managed Care 12(4): 36-44.
- Pearce, D. J., K. H. Stealey, et al. (2006). "Psoriasis treatment in the United States at the end of the 20th century." International Journal of Dermatology 45(4): 370-374.
- Pitarch, G., J. L. Sanchez-Carazo, et al. (2007). "Treatment of psoriasis with adalimumab." Clinical & Experimental Dermatology 32(1): 18-22.
- Poulalhon, N., E. Begon, et al. (2007). "A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: Evidence for efficacy and high incidence of biological autoimmunity." British Journal of Dermatology 156(2): 329-336.
- Ricardo, R. R., M. Rhoa, et al. (2004). "Clinical benefits in patients with psoriasis after efalizumab therapy: clinical trials versus practice." Cutis 74(3): 193-200.
- Rich, S. J. and C. E. Bello-Quintero (2004). "Advancements in the treatment of psoriasis: role of biologic agents." Journal of Managed Care Pharmacy 10(4): 318-25.
- Rodewald, E. J., T. S. Housman, et al. (2001). "The efficacy of 308nm laser treatment of psoriasis compared to historical controls." Dermatology Online Journal 7(2): 4.
- Saini, R., W. D. Tutrone, et al. (2005). "Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus." Current Pharmaceutical Design 11(2): 273-80.
- San Filippo, J. and R. E. Kalb (2005). "Case report: Infliximab treatment for recalcitrant psoriasis and psoriatic arthritis." Cosmetic Dermatology 18(9): 645-646.
- Sanchez Carazo, J. L., L. Mahiques Santos, et al. (2006). "Safety of etanercept in psoriasis: a critical review." Drug Safety 29(8): 675-85.
- Sauder, D. N. and A. J. Mamelak (2004). "Understanding the new clinical landscape for psoriasis: a comparative review of biologics." Journal of Cutaneous Medicine & Surgery 8(4): 205-12.
- Scheinfeld, N. (2004). "Off-label uses and side effects of infliximab." Journal of Drugs in Dermatology: JDD 3(3): 273-84.
- Schopf, R. E., H. Aust, et al. (2002). "Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α , infliximab." Journal of the American Academy of Dermatology 46(6): 886-891.
- Smith, C. H., K. Jackson, et al. (2006). "Infliximab for severe, treatment-resistant psoriasis: A prospective, open-label study." British Journal of Dermatology 155(1): 160-169.
- Sobell, J. M. and S. J. Hallas (2003). "Systemic therapies for psoriasis: understanding current and newly emerging therapies." Seminars in Cutaneous Medicine & Surgery 22(3): 187-95.
- Spuls, P. I., S. Hadi, et al. (2003). "Retrospective analysis of the treatment of psoriasis of the palms and soles." Journal of Dermatological Treatment 14 Suppl 2: 21-5.
- Sridhar, J., P. L. K. Desylva, et al. (2006). "Chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in psoriasis." Indian Journal of Dermatology, Venereology & Leprology 72(2): 133-135.
- Strober, B. E. (2005). "The treatment of psoriasis with etanercept." Seminars in Cutaneous Medicine & Surgery 24(1): 28-36.
- Strober, B. E. and S. Clarke (2004). "Etanercept for the treatment of psoriasis: combination therapy with other modalities." Journal of Drugs in Dermatology: JDD 3(3): 270-2.
- Sukal, S. A., L. Nadiminti, et al. (2006). "Etanercept and demyelinating disease in a patient with psoriasis." Journal of the American Academy of Dermatology 54(1): 160-164.
- Sun, Y. N., J. F. Lu, et al. (2005). "Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects." Journal of Clinical Pharmacology 45(4): 468-476.
- Tobin, A.-M. and B. Kirby (2005). "TNF α inhibitors in the treatment of psoriasis and psoriatic arthritis." Biodrugs 19(1): 47-57.

- Tutrone, W. D., M. H. Kagen, et al. (2001). "Biologic therapy for psoriasis: a brief history, II." Cutis 68(6): 367-72.
- Tutrone, W. D., R. Saini, et al. (2004). "Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept." Idrugs 7(1): 45-9.
- van de Kerkhof, P. C. M. (2006). "Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments." Journal of the European Academy of Dermatology & Venereology 20(6): 639-50.
- Victor, F. C. and A. B. Gottlieb (2002). "TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis." Journal of Drugs in Dermatology: JDD 1(3): 264-75.
- Vugmeyster, Y., T. Kikuchi, et al. (2004). "Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin." Clinical Immunology 113(1): 38-46.
- Weinberg, J. M. (2003). "An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis." Clinical Therapeutics 25(10): 2487-505.
- Weinberg, J. M., R. Saini, et al. (2002). "Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept." Journal of Drugs in Dermatology: JDD 1(3): 303-10.
- Wilsmann-Theis, D., S. Martin, et al. (2006). "Biologics dramatic advances in the treatment of psoriasis." Current Pharmaceutical Design 12(8): 989-99.
- Winterfield, L. and A. Menter (2004). "Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade." Dermatologic Clinics 22(4): 437-47.
- Winterfield, L. S. and A. Menter (2004). "Infliximab." Dermatologic Therapy 17(5): 409-26.
- Yamauchi, P. S., V. Gindi, et al. (2004). "The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety." Dermatologic Clinics 22(4): 449-59.
- Young, M. S. (2003). "Preparing dermatology nurses: biologic therapy for psoriasis." Dermatology Nursing 15(5): 413-6.
- Yung, R. L. (2001). "Etanercept Immunex." Current Opinion in Investigational Drugs 2(2): 216-21.
- Zeltser, R., L. Valle, et al. (2001). "Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: A recombinant tumor necrosis factor alpha receptor: Fc fusion protein." Archives of Dermatology 137(7): 893-899.
- Zeltser, R., L. Valle, et al. (2001). "Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.[see comment]." Archives of Dermatology 137(7): 893-9.
- Zhou, H. (2005). "Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein." Journal of Clinical Pharmacology 45(5): 490-7.
- Zhou, H., A. Patat, et al. (2004). "Absence of a pharmacokinetic interaction between etanercept and warfarin." Journal of Clinical Pharmacology 44(5): 543-50.
- Zhou, H., V. Parks, et al. (2004). "Absence of a clinically relevant interaction between etanercept and digoxin." Journal of Clinical Pharmacology 44(11): 1244-51.

Reviews or Papers referring to Already-Identified RCTs (n=13)

- Boehncke, W.-H., J. Prinz, et al. (2006). "Biologic therapies for psoriasis. A systematic review." Journal of Rheumatology 33(7): 1447-51.
- Feldman, S. R., A. B. Kimball, et al. (2005). "Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial." Journal of the American Academy of Dermatology 53(5): 887-9.
- Feldman, S. R., K. B. Gordon, et al. (2005). "Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial." British Journal of Dermatology 152(5): 954-60.

- Gottlieb, A. B., B. Miller, et al. (2003). "Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis." Journal of Cutaneous Medicine & Surgery 7(3): 198-207.
- Gottlieb, A. B., U. Chaudhari, et al. (2003). "Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis." Journal of the American Academy of Dermatology 48(6): 829-35.
- Jordan, J. K. (2005). "Efalizumab for the treatment of moderate to severe plaque psoriasis." Annals of Pharmacotherapy 39(9): 1476-82.
- Menter, A., C. L. Leonardi, et al. (2006). "Long-term management of plaque psoriasis with continuous efalizumab therapy." Journal of the American Academy of Dermatology 54(4 Suppl 1): S182-8.
- Menter, A., K. Gordon, et al. (2005). "Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis." Archives of Dermatology 141(1): 31-8.
- Menter, A., M. Kosinski, et al. (2004). "Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis." Journal of Drugs in Dermatology: JDD 3(1): 27-38.
- Ortonne, J.-P., N. Shear, et al. (2005). "Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]." BMC Dermatology 5: 13.
- Pariser, D. M., K. B. Gordon, et al. (2005). "Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I." Journal of Cutaneous Medicine & Surgery 9(6): 303-12.
- Reich, K., F. O. Nestle, et al. (2006). "Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial." British Journal of Dermatology 154(6): 1161-8.
- Smith, C. H., A. V. Anstey, et al. (2005). "British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005." British Journal of Dermatology 153(3): 486-97.